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METHODOLOGY Open Access
The adaptive designs CONSORT extension
(ACE) statement: a checklist with
explanation and elaboration guideline for
reporting randomised trials that use an
adaptive design
Munyaradzi Dimairo1* , Philip Pallmann2, James Wason3,4, Susan Todd5, Thomas Jaki6, Steven A. Julious1,
Adrian P. Mander2,3, Christopher J. Weir7, Franz Koenig8, Marc K. Walton9, Jon P. Nicholl1, Elizabeth Coates1,
Katie Biggs1, Toshimitsu Hamasaki10, Michael A. Proschan11, John A. Scott12, Yuki Ando13, Daniel Hind1,
Douglas G. Altman14 and on behalf of the ACE Consensus Group
Abstract
Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of
conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The
reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised
trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to
inform practice as well as future research and contributes to research waste. Better transparency and adequate
reporting will enable the potential benefits of ADs to be realised.
This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to
enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension
(ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical
trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of
the CONSORT Group were involved during the development process.
The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with
examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified
items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20
unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified
item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further
explanatory text.
The intention is to enhance transparency and improve reporting of AD randomised trials to improve the
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interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to
facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits. In
order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal websites.
“To maximise the benefit to society, you need to not just do research but do it well” Douglas G Altman
Purpose of the paper
Incomplete and poor reporting of randomised clinical
trials makes trial findings difficult to interpret due to
study methods, results, and inference that are not repro-
ducible. This severely undermines the value of scientific
research, obstructs robust evidence synthesis to inform
practice and future research, and contributes to research
waste [1, 2]. The Consolidated Standards Of Reporting
Trials (CONSORT) statement is a consensus-based re-
porting guidance framework that aims to promote and
enhance transparent and adequate reporting of rando-
mised trials [3, 4]. Specific CONSORT extensions ad-
dressing the reporting needs for particular trial designs,
hypotheses, and interventions have been developed [5].
The use of reporting guidelines is associated with im-
proved completeness in study reporting [6–8]; however,
mechanisms to improve adherence to reporting guide-
lines are needed [9–12].
We developed an Adaptive designs CONSORT Exten-
sion (ACE) [13] to the CONSORT 2010 statement [3, 4]
to support reporting of randomised trials that use an
adaptive design (AD)—referred to as AD randomised tri-
als. In this paper, we define an AD and summarise some
types of ADs as well as their use and reporting. We then
describe briefly how the ACE guideline was developed,
and present its scope and underlying principles. Finally,
we present the ACE checklist with explanation and elab-
oration (E&E) to guide its use.
Adaptive designs: definition, current use, and
reporting
The ACE Steering Committee [13] agreed a definition of
an AD (Box 1) consistent with the literature [14–18].
Box 1 Definition of an adaptive design (AD)
A clinical trial design that offers pre-planned opportunities to use accu-
mulating trial data to modify aspects of an ongoing trial while preserv-
ing the validity and integrity of that trial.
Substantial uncertainties often exist when designing
trials around aspects such as the target population,
outcome variability, optimal treatments for testing,
treatment duration, treatment intensity, outcomes to
measure, and measures of treatment effect [19]. Well
designed and conducted AD trials allow researchers to
address research questions more efficiently by allowing
key aspects or assumptions of ongoing trials to be
evaluated or validly stopping treatment arms or entire
trials on the basis of available evidence [15, 18, 20, 21].
As a result, patients may receive safe, effective treatments
sooner than with fixed (non-adaptive) designs [19, 22–25].
Despite their potential benefits, there are practical
challenges and obstacles to the use of ADs [18, 26–33].
The literature on ADs is considerable, and there is
specific terminology associated with the field. Box 2
gives a glossary of key terminology used throughout this
E&E document.
Box 2 Definitions of key technical terms
Validity—The ability to provide correct statistical inference to establish
effects of study interventions and produce accurate estimates of effects
(point estimates and uncertainty), to give results that are convincing to
the broader audience (science community and consumers of research
findings).
Integrity—Relates to minimisation of operational bias, maintenance of
data confidentiality, and ensuring consistency in trial conduct (before
and after adaptations) for credibility, interpretability, and persuasiveness
of trial results.
Pre-planned adaptations or adaptive features—Pre-planned or
prespecified changes or modifications to be made to aspects of an
ongoing trial, which are specified at the design stage or at least before
seeing accumulating trial data by treatment group, and are
documented for audit trail (such as in the protocol).
Unplanned changes—Ad hoc modifications to aspects of an ongoing
trial.
Type of AD—The main category used to classify a trial design by its pre-
planned adaptive features or adaptations. Some ADs can fall into more
than one main category of trial adaptation (see Table 1).
Adaptive decision-making criteria—Elements of decision-making rules de-
scribing whether, how, and when the proposed trial adaptations will be
used during the trial. It involves pre-specifying a set of actions guiding
how decisions about implementing the trial adaptations are made given
interim observed data (decision rules). It also involves pre-specifying
limits or parameters to trigger trial adaptations (decision boundaries).
For example, stopping boundaries that relate to pre-specified limits re-
garding decisions to stop the trial or treatment arm(s) early.
Interim analysis—A statistical analysis or review of accumulating data
from an ongoing trial (interim data) to inform trial adaptations (before
the final analysis), which may or may not involve treatment group
comparisons.
Binding rules—Decision rules that must be adhered to for the design to
control the false positive error rate.
Non-binding rules—Optional decision rules that can be overruled
without negative effects on control of the false positive error rate.
Statistical properties or operating characteristics—Relates to behaviour of
the trial design. These may include statistical power, false positive error
rate, bias in estimation of treatment effect(s), or probability of each
adaptation taking place.
Simulation—A computational procedure performed using a computer
program to evaluate statistical properties of the design by generating
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pseudo data according to the design, under a number of scenarios and
repeated a large number of times.
Fixed (non-adaptive) design—A clinical trial that is designed with an
expected fixed sample size without any scope for pre-planned changes
(adaptations) of any study design feature.
Bias—The systematic tendency for the treatment effect estimates to
deviate from their “true values”; including the statistical properties (such
as error rates) to deviate from what is expected in theory (such as pre-
specified nominal error rate).
Operational bias—Occurs when knowledge of key trial-related informa-
tion influences changes to the conduct of that trial in a manner that
biases the conclusions made regarding the benefits and/or harms of
study treatments.
Statistical bias—Bias introduced to the study results or conclusions by
the design: for example, as a result of changes to aspects of the trial or
multiple analyses of accumulating data from an ongoing trial.
Subpopulation(s)—Subset(s) of the trial population that can be classified
by characteristics of participants that are thought to be associated with
treatment response (such as genetic markers or biomarkers).
Adaptation outcome(s)—Outcome(s) used to guide trial adaptation(s);
they may be different from the primary outcome(s).
Table 1 summarises some types of ADs and cites
examples of their use in randomised trials. The
motivations for these trial adaptations are well discussed
[15, 18, 21, 22, 25, 103–105]. Notably, classification of
ADs in the literature is inconsistent [13, 22], while the
scope and complexity of trial adaptations and
underpinning statistical methods continues to broaden
[18, 20, 106].
Furthermore, there is growing literature citing AD
methods [29, 78, 107] and interest in their application
by researchers and research funders [26, 28, 108].
Regulators have published reflection and guidance
papers on ADs [14, 108–111]. Several studies, including
regulatory reviews, have investigated the use of ADs in
randomised trials [27, 29, 31, 33, 37, 45, 97, 107, 108,
112–119]. In summary, ADs are used in a relatively low
proportion of trials, although their use is steadily
increasing in both the public and private sectors [114–
116], and they are frequently considered at the design
stage [27].
The use of ADs is likely to be underestimated due to
poor reporting making it difficult to retrieve them in the
literature [114]. While the reporting of standard
CONSORT requirements of AD randomised trials is
generally comparable to that of traditional fixed design
trials [45], inadequate and inconsistent reporting of
essential aspects relating to ADs is widely documented
[26, 27, 45, 107, 112, 113, 120–122]. This may limit their
credibility, the interpretability of results, and their ability
to inform or change practice [14, 26–28, 30, 31, 108,
109, 112, 119, 120], whereas transparency and adequate
Table 1 Some types of adaptations used in randomised trials with examples
Trial adaptive feature or adaptation, motivation, and cited examples of
use
Type of adaptive design (AD) and examples of underlying statistical
methods
Changing the predetermined sample size in response to inaccurate
assumptions of study design parameters to achieve the desired statistical
power [34–36].
Sample size re-estimation, re-assessment, or re-calculation (SSR) using ag-
gregated interim data from all participants or interim data separated ac-
cording to allocated treatment [37–44].
Stopping the trial early for efficacy, futility, or safety when there is
sufficient evidence [45, 46].
Group sequential design (GSD) [47, 48]; information-based GSD [49]; futil-
ity assessment using stochastic curtailment [50–52].
Evaluating multiple treatments in one trial allowing for early selection of
promising treatments or dropping futile or unsafe treatments [53–55].
New treatments can also be added to an ongoing trial [56].
Multi-arm multi-stage (MAMS), dose/treatment-selection, drop-the-loser,
or pick-the-winner, or add arm [23, 57–66].
Changing the treatment allocation ratio to favour treatments indicating
beneficial effects [67, 68].
Response-adaptive randomisation (RAR) [68–73].
Investigating multiple research objectives that are traditionally examined
in distinct trial phases, in one trial under a single protocol [74–76]. For
instance, addressing learning (selecting promising treatments for further
testing) and confirmatory objectives in one trial.
Operationally or inferentially seamless AD [63–65, 77–79].
Adjusting the trial population or selecting patients with certain
characteristics that are most likely to benefit from investigative
treatments [80–83]. This may involve incorporating statistical information
from or adapting on a biomarker.
Population or patient enrichment or biomarker AD [84–88].
Changing the primary research hypotheses or objectives or primary
endpoints [78, 89]. For example, switching from non-inferiority to
superiority.
Adaptive hypotheses [58, 90].
Switching the allocated treatment of patients to an alternative treatment
influenced by ethical considerations, for instance, due to lack of benefit
or safety issues.
Adaptive treatment-switching [91, 92].
Combination of at least two types of adaptations [24, 36, 89, 93–98]. Multiple ADs such as GSD or drop-the-loser with SSR [99]; inferentially
seamless phase 2/3 AD with hypotheses selection [77] or population en-
richment [100]; biomarker-stratified with RAR [101]; adaptive platform trials
where arms can be added or stopped early [19, 24, 102].
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reporting can help address these concerns [22, 27]. In
summary, statistical and non-statistical issues arise in
ADs [22, 97, 105, 108, 123–127], which require special
reporting considerations [13].
Summary of how the ACE guideline was
developed
We adhered to a registered protocol [128] and the
consensus-driven methodological framework for devel-
oping healthcare reporting guidelines recommended by
the CONSORT Group and the Enhancing the QUAlity
and Transparency Of health Research (EQUATOR) Net-
work [129]. An open access paper detailing the rationale
and the complete development process of the ACE
checklist for main reports and abstracts has been pub-
lished [13]. That paper details how reporting items were
identified, the stakeholders who were involved, the
decision-making process, consensus judgement and how
reporting items were retained or dropped, and finalisa-
tion of the ACE checklist. In summary, this comprised a
two-stage Delphi process involving cross-sector (public
and private) and multidisciplinary key stakeholders in
clinical trials research from 21 countries. Delphi survey
response rates were 94/143 (66%), 114/156 (73%), and
79/143 (55%) in round one, round two, and across both
rounds, respectively. A consensus meeting attended by
27 cross-sector delegates from Europe, Asia, and the US
followed this. Members of the CONSORT Group pro-
vided oversight throughout. The ACE Consensus Group
and Steering Committee approved the final checklist
that included the abstract and contributed to this E&E
document. Box 3 outlines the scope of principles guiding
the application of this extension.
Box 3 ACE guideline scope and general principles
1. It applies to all randomised clinical trials using an adaptive design
(AD), as defined in Box 1.
2. It excludes randomised clinical trials that change aspects of an
ongoing trial based entirely on external information [130] or with
internal pilots focusing solely on feasibility and processes (such as
recruitment, intervention delivery, and data completeness) [131].
3. It covers general reporting principles to make it applicable to a wide
range of current and future ADs and trial adaptations.
4. It is not intended to promote or discourage the use of any specific
type of AD, trial adaptation, or frequentist or Bayesian statistical
methods. These choices should be driven by the scientific research
questions, the goals behind the use of the proposed AD features, and
practical considerations [22].
5. It aims to promote transparent and adequate reporting of AD
randomised trials to maximise their potential benefits and improve
the interpretability of their results and their reproducibility, without
impeding their appropriate use or stifling design innovation.
Therefore, the guideline does not specifically address the
appropriateness of adaptive statistical methods.
6. It presents the minimum requirements that should be reported but
we also encourage authors to report additional information that may
enhance the interpretation of trial findings.
7. Access to information is most important regardless of the source and
form of publication. For example, use of appendices and citation of
accessible material (such as protocols, statistical analysis plans (SAPs),
(Continued)
or related publications) is often sufficient.
8. The order in which researchers report information does not
necessarily need to follow the order of the checklist.
9. The guideline does not primarily address specific reporting needs for
non-randomised ADs (such as phase I dose escalation studies, phase II
single-arm designs). However, some principles covered here may still
apply to such trials.
Structure of the ACE guideline
Authors should apply this guideline together with the
CONSORT 2010 statement [3, 4] and any other relevant
extensions depending on other design features of their
AD randomised trial (such as extensions for multi-arm
[132], cluster randomised [133], crossover [134], and
non-inferiority and equivalence trials [135]). Box 4 sum-
marises the changes made to develop this extension.
Table 2 shows which CONSORT 2010 items were
adapted and how. We provide both CONSORT 2010
and ACE items with comments, explanation, and exam-
ples to illustrate how specific aspects of different types
of AD randomised trials should be reported. For the ex-
amples, we obtained some additional information from
researchers or other trial documents (such as statistical
analysis plans (SAPs) and protocols). Headings of exam-
ples indicate the type of AD and the specific elements of
an item that were better reported, so examples may in-
clude some incomplete reporting in relation to other
elements.
Box 4 Summary of significant changes to the CONSORT 2010
statement
New items—Introduces seven new items that are specific to AD
randomised trials
▪ 3b on pre-planned AD features,
▪ 11c on confidentiality and minimisation of operational bias,
▪ 12b on estimation and inference methods,
▪ 14c on adaptation decisions,
▪ 15b on similarity between stages,
▪ 17c on interim results and,
▪ 24b on SAP and other relevant trial documents.
Restructuring—Renumbers four standard items to accommodate the
new items
▪ 3b is now 3c (on losses and exclusions) to accommodate the new
item 3b,
▪ 12b is now 12c (on methods for additional analyses) to accommodate
the new item 12b,
▪ 15 on baseline demographics and clinical characteristics is now 15a to
accommodate new item 15b and,
▪ 24 on access to protocol is now 24a to accommodate new item 24b.
Modified items—Modifies nine standard items
▪ 3b (now 3c) on important changes to the design or methods after
commencement,
▪ 6a on pre-specified primary and secondary outcomes,
▪ 6b on changes to trial outcomes after commencement,
▪ 7a on sample size,
▪ 7b on interim analyses and stopping rules, which is now a
replacement capturing adaptive decision-making criteria to guide
adaptation(s),
▪ 8b on type of randomisation,
▪ 12a on statistical methods to compare groups,
▪ 13a on participants randomised, treated, and analysed,
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▪ 14a on dates for recruitment and follow-up.
Expanded text—Expands the E&E text for clarification on six items
without changes to item wording
▪ 14b on why the trial ended or was stopped,
▪ 15 (now 15a) on baseline demographics and clinical characteristics,
▪ 16 on numbers randomised,
▪ 17a on primary and secondary outcome results,
▪ 20 on limitations and,
▪ 21 on generalisability.
Restructuring—Renames two subsection headings to reflect new ACE
content
▪ “recruitment” renamed to “recruitment and adaptations”
▪ “sample size” renamed to “sample size and operating characteristics”
Restructuring—Introduces a new subsection heading
▪ “Statistical analysis plan and other trial-related documents” to accom-
modate item 24b
Modifies abstract item 1b and introduces an extension for journal
and conference abstracts
New item—Introduces one new item (on adaptation decisions made)
On “adaptation decisions made”
Modified item—Modifies one standard item
On “trial design”
Expanded text—Expands the E&E text for clarification on one item for
certain ADs in particular circumstances without changes to item
wording
On “outcome”
Item numbers or section/topic referenced here are presented in Tables
2 and 3
The ACE checklist
Tables 2 and 3 are checklists for the main report and
abstract, respectively. Only new and modified items are
discussed in this E&E document, as well as six items
that retain the CONSORT 2010 [3, 4] wording but
require clarification for certain ADs (Box 4). Authors
should download and complete Additional file 1 to
accompany a manuscript during journal submission.
Section 1. Title and abstract
CONSORT 2010 item 1b: Structured summary of trial
design, methods, results, and conclusions (for specific
guidance see CONSORT for abstracts [136, 137]).
ACE item 1b: Structured summary of trial design,
methods, results, and conclusions (for specific guidance
see ACE for abstracts, Table 3).
Explanation—A well structured abstract summary
encompassing trial design, methods, results, and con-
clusions is essential regardless of the type of design
implemented [137]. This allows readers to search for
relevant studies of interest and to quickly judge if the
reported trial is relevant to them for further reading.
Furthermore, it helps readers to make instant judge-
ments on key benefits and risks of study interventions.
Table 3 presents minimum essential items authors
should report in an AD randomised trial abstract.
Authors should use this extension together with the
CONSORT for journal and conference abstracts for
additional details [136, 137] and other relevant extensions
where appropriate.
CONSORT abstract item (Trial design): Description of
the trial design (for example, parallel, cluster, non-
inferiority).
ACE abstract item (Trial design): Description of the
trial design (for example, parallel, cluster, non-
inferiority); include the word “adaptive” in the content or
at least as a keyword.
Explanation—AD randomised trials should be indexed
properly to allow other researchers to easily retrieve
them in literature searches. This is particularly im-
portant as trial design may influence interpretation of
trial findings and the evidence synthesis approach used
during meta-analyses. The MEDLINE database provides
“Adaptive clinical trial” as a Medical Subject Heading
(MeSH) topic to improve indexing [139]. Authors may
also like to state the type of the AD, including details of
adaptations as covered under the new item 3b (Table 3).
See Box 5 for exemplars.
Box 5 Exemplars on the use of “adaptive” in the abstract
content and/or as a keyword
Example 1. Abstract (title)
“Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a
randomized, double-blinded, placebo-controlled phase 2 trial using
Bayesian adaptive design (the SPRINT trial).” [140]
Example 2. Abstract (background)
“The drug development process can be streamlined by combining the
traditionally separate stages of dose-finding (Phase IIb) and confirmation
of efficacy and safety (Phase III) using an adaptive seamless design.”
[141]
Example 3. Abstract (aims) and keyword
“AWARD-5 was an adaptive, seamless, double-blind study comparing
dulaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor
agonist, with placebo at 26 weeks and sitagliptin up to 104 weeks.” and
keyword “Bayesian adaptive” [93]
CONSORT/ACE abstract item (Outcome): Clearly
defined primary outcome for this report.
Explanation—In some AD randomised trials, the
outcome used to inform adaptations (adaptation out-
come) and the primary outcome of the study can differ
(see item 6 of the main checklist for details). The
necessity of reporting both of these outcomes and
results in the abstract depends on the stage of reporting
and whether the adaptation decisions made were critical
to influencing the interpretation of the final results. For
example, when a trial or at least a treatment group is
stopped early, based on an adaptation outcome which is
not the primary outcome, it becomes essential to
adequately describe both outcomes in accordance with
the CONSORT 2010 statement [3, 4]. Contrarily, only
the description of the primary outcome in the abstract
will be essential when non-terminal adaptation decisions
are made (such as to change the sample size, update
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Table 2 ACE checklist for the main report
Section/ Topic Item No Standard CONSORT 2010 checklist item Extension for adaptive design randomised trials Page
No
Title and abstract 1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results,
and conclusions (for specific guidance see CONSORT
for abstracts) [136, 137]
Structured summary of trial design, methods, results,
and conclusions (for specific guidance see ACE for
abstracts, Table 3)
Introduction
Background and
objectives
2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial)
including allocation ratio
3b«a Type of adaptive design used, with details of the pre-
planned trial adaptations and the statistical informa-
tion informing the adaptations
3c«3bb Important changes to methods after trial
commencement (such as eligibility criteria), with
reasons
Important changes to the design or methods after
trial commencement (such as eligibility criteria)
outside the scope of the pre-planned adaptive design
features, with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details
to allow replication, including how and when they
were actually administered
Outcomes 6ab Completely defined pre-specified primary and second-
ary outcome measures, including how and when they
were assessed
Completely define pre-specified primary and second-
ary outcome measures, including how and when
they were assessed. Any other outcome measures
used to inform pre-planned adaptations should be
described with the rationale
6bb Any changes to trial outcomes after the trial
commenced, with reasons
Any unplanned changes to trial outcomes after the
trial commenced, with reasons
Sample size and
operating
characteristics
7ab How sample size was determined How sample size and operating characteristics were
determined
7bc When applicable, explanation of any interim analyses
and stopping guidelines
Pre-planned interim decision-making criteria to guide
the trial adaptation process; whether decision-making
criteria were binding or non-binding; pre-planned
and actual timing and frequency of interim data looks
to inform trial adaptations
Randomisation
Sequence
generation
8a Method used to generate the random allocation
sequence
8bb Type of randomisation; details of any restriction (such
as blocking and block size)
Type of randomisation; details of any restriction (such
as blocking and block size); any changes to the
allocation rule after trial adaptation decisions; any
pre-planned allocation rule or algorithm to update
randomisation with timing and frequency of updates
Allocation
concealment
mechanism
9 Mechanism used to implement the random allocation
sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence
until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who
enrolled participants, and who assigned participants to
interventions
Blinding 11a If done, who was blinded after assignment to
interventions (for example, participants, care providers,
those assessing outcomes) and how
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Table 2 ACE checklist for the main report (Continued)
Section/ Topic Item No Standard CONSORT 2010 checklist item Extension for adaptive design randomised trials Page
No
11b If relevant, description of the similarity of interventions
11ca Measures to safeguard the confidentiality of interim
information and minimise potential operational bias
during the trial
Statistical methods 12ab Statistical methods used to compare groups for
primary and secondary outcomes
Statistical methods used to compare groups for
primary and secondary outcomes, and any other
outcomes used to make pre-planned adaptations
12b«a For the implemented adaptive design features,
statistical methods used to estimate treatment effects
for key endpoints and to make inferences
12c«12b Methods for additional analyses, such as subgroup
analyses and adjusted analyses
Results
Participant flow (a
diagram is strongly
recommended)
13ab For each group, the numbers of participants who
were randomly assigned, received intended treatment,
and were analysed for the primary outcome
For each group, the numbers of participants who
were randomly assigned, received intended
treatment, and were analysed for the primary
outcome and any other outcomes used to inform
pre-planned adaptations, if applicable
13b For each group, losses and exclusions after
randomisation, together with reasons
Recruitment and
adaptations
14ab Dates defining the periods of recruitment and follow-
up
Dates defining the periods of recruitment and follow-
up, for each group
14bd Why the trial ended or was stopped See expanded E&E text for clarification
14ca Specify what trial adaptation decisions were made in
light of the pre-planned decision-making criteria and
observed accrued data
Baseline data 15a«15d A table showing baseline demographic and clinical
characteristics for each group
See expanded E&E text for clarification
15ba Summary of data to enable the assessment of
similarity in the trial population between interim
stages
Numbers analysed 16d For each group, number of participants (denominator)
included in each analysis and whether the analysis
was by original assigned groups
See expanded E&E text for clarification
Outcomes and
estimation
17ad For each primary and secondary outcome, results for
each group, and the estimated effect size and its
precision (such as 95% confidence interval)
See expanded E&E text for clarification
17b For binary outcomes, presentation of both absolute
and relative effect sizes is recommended
17ca Report interim results used to inform interim
decision-making
Ancillary analyses 18 Results of any other analyses performed, including
subgroup analyses and adjusted analyses,
distinguishing pre-specified from exploratory
Harms 19 All important harms or unintended effects in each
group (for specific guidance see CONSORT for harms)
[138]
Discussion
Limitations 20d Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
See expanded E&E text for clarification
Generalisability 21d Generalisability (external validity, applicability) of the
trial findings
See expanded E&E text for clarification
Interpretation 22 Interpretation consistent with results, balancing
benefits and harms, and considering other relevant
evidence
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Table 2 ACE checklist for the main report (Continued)
Section/ Topic Item No Standard CONSORT 2010 checklist item Extension for adaptive design randomised trials Page
No
Other information
Registration 23 Registration number and name of trial registry
Protocol 24a«24 Where the full trial protocol can be accessed
SAP and other
relevant trial
documents
24ba Where the full statistical analysis plan and other
relevant trial documents can be accessed
Funding 25 Sources of funding and other support (such as supply
of drugs), role of funders
“X« Y” means original CONSORT 2010 item Y has been renumbered to X;
“X«” means item reordering resulted in new item X replacing the number of the original CONSORT 2010″ item X”;
ACE Adaptive designs CONSORT Extension, E&E explanation and elaboration, SAP statistical analysis plan
aNew items that should only be applied in reference to ACE;
bModified items that require reference to both CONSORT 2010 and ACE;
cReplacement (modified) item that only requires reference to ACE;
dItem wording remains unchanged in reference to CONSORT 2010 but we expanded the ACE explanatory text to clarify additional considerations for certain
adaptive designs. These unchanged items require reference to CONSORT 2010 except for item 14b
Table 3 ACE checklist for abstracts
Section/Topic Standard checklist description Extension for adaptive design randomised trials
Title Identification of study as randomised
Authors Contact details for the corresponding author
Trial designa Description of the trial design (for example, parallel,
cluster, non-inferiority)
Description of the trial design (for example,
parallel, cluster, non-inferiority); include the
word “adaptive” in the content or at least as a keyword
Methods
Participants Eligibility criteria for participants and the settings
where the data were collected
Interventions Interventions intended for each group
Objective Specific objective or hypothesis
Outcomeb Clearly defined primary outcome for this report See expanded E&E text for clarification
Randomisation How participants were allocated to interventions
Blinding (masking) Whether or not participants, care givers, and those assessing
the outcomes were blinded to group assignment
Results
Numbers randomised Number of participants randomised to each group
Recruitment Trial status
Adaptation decisions madec Specify what trial adaptation decisions were made
in light of the pre-planned decision-making criteria
and observed accrued data
Numbers analysed Number of participants analysed in each group
Outcome For the primary outcome, a result for each group and
the estimated effect size and its precision
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
E&E = explanation and elaboration
aModified items that require reference to both CONSORT for abstracts [136, 137] and ACE;
bItem wording remains unchanged in reference to CONSORT for abstracts [136, 137], but we expanded the ACE explanatory text to clarify additional
considerations for certain adaptive designs;
cNew items that should only be applied in reference to ACE
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randomisation, or no dropping of treatments groups at
interims) and when final (not interim) results are being
reported. Furthermore, the results item (Table 3) should
be reported consistent with the stated primary and
adaptation outcome(s), where necessary. See Box 6 for
exemplars.
Box 6 Exemplars on reporting outcomes in the abstract
Example 1. Bayesian RAR dose finding AD with early stopping for efficacy
or futility
“The primary outcome required, first, a greater than 90% posterior
probability that the most promising levocarnitine dose decreases the
Sequential Organ Failure Assessment (SOFA) score at 48 h and, second
(given having met the first condition), at least a 30% predictive
probability of success in reducing 28-day mortality in a subsequent trad-
itional superiority trial to test efficacy.” [142]
Example 2. Sequential-step AD
“The primary efficacy endpoint was definitive cure (absence of parasites
in tissue aspirates) at 6 months. If interim analyses, based on initial cure
evaluated 30 days after the start of treatment…“ [143]
ACE abstract item (adaptation decisions made): Specify
what trial adaptation decisions were made in light of the
pre-planned decision-making criteria and observed ac-
crued data.
Explanation—A brief account of changes that were
made to the trial, on what basis they were made, and
when is important. The fact that the design allows for
adaptations will influence interpretation of results,
potentially due to operational and statistical biases. If
changes should have been made, but were not, then this
may further influence credibility of results. See the main
checklist item 14c for details. See Box 7 for exemplars.
Box 7 Exemplars on reporting adaptation decisions made to
the trial in the abstract
Example 1. 2-stage inferential seamless phase 2/3 AD; pre-planned adapta-
tion decisions
“A planned interim analysis was conducted for otamixaban dose
selection using a pre-specified algorithm (unknown to investigators) …
The selected regimen to carry forward was an intravenous bolus of
0.080 mg/kg followed by an infusion of 0.140 mg/kg per hour.” [144]
Example 2. Group sequential AD; early stopping decision
“The trial was stopped early (at the third interim analysis), according to
pre-specified rules, after a median follow-up of 27 months, because the
boundary for an overwhelming benefit with LCZ696 had been crossed.”
[145]
Section 3: Methods (Trial design)
ACE item 3b (new): Type of adaptive design used, with
details of the pre-planned adaptations and the statistical
information informing the adaptations.
Explanation—A description of the type of AD in-
dicates the underlying design concepts and the ap-
plicable adaptive statistical methods. Although there is
an inconsistent use of nomenclature to classify ADs,
together with growing related methodology [13], some
currently used types of ADs are presented in Table 1. A
clear description will also improve the indexing of AD
methods and for easy identification during literature
reviews.
Specification of pre-planned opportunities for adapta-
tions and their scope is essential to preserve the integrity
of AD randomised trials [22] and for regulatory assess-
ments, regardless of whether they were triggered during
the trial [14, 108, 109]. Details of pre-planned adapta-
tions enable readers to assess the appropriateness of
statistical methods used to evaluate operating character-
istics of the AD (item 7a) and for performing statistical
inference (item 12b). Unfortunately, pre-planned adapta-
tions are commonly insufficiently described [119]. Au-
thors are encouraged to explain the scientific rationale
for choosing the considered pre-planned adaptations en-
capsulated under the CONSORT 2010 item “scientific
background and explanation of rationale” (item 2a). This
rationale should focus on the goals of the considered ad-
aptations in line with the study objectives and hypoth-
eses (item 2b) [107, 108, 119, 123].
Details of pre-planned adaptations with rationale
should be documented in accessible study documents
for readers to be able to evaluate what was planned and
unplanned (such as protocol, interim and final SAP or
dedicated trial document). Of note, any pre-planned
adaptation that modifies eligibility criteria (such as in
population enrichment ADs [88, 146]) should be clearly
described.
Adaptive trials use accrued statistical information to
make pre-planned adaptation(s) (item 14c) at interim
analyses guided by pre-planned decision-making criteria
and rules (item 7b). Reporting this statistical information
for guiding adaptations and how it is gathered is para-
mount. Analytical derivations of statistical information
guiding pre-planned adaptations using statistical models
or formulae should be described to facilitate reproduci-
bility and interpretation of results. The use of supple-
mentary material or references to published literature is
sufficient. For example, sample size re-assessment (SSR)
can be performed using different methods with or with-
out knowledge or use of treatment arm allocation [37,
38, 40, 44]. Around 43% (15/35) of regulatory submis-
sions needed further clarifications because of failure to
describe how a SSR would be performed [119]. Early
stopping of a trial or treatment group for futility can be
evaluated based on statistical information to support
lack of evidence of benefit that is derived and expressed
in several ways. For example, conditional power [52,
147–150], predictive power [51, 148, 151–153], the
threshold of the treatment effect, posterior probability of
the treatment effect [96], or some form of clinical utility
that quantifies the balance between benefits against harms
[154, 155] or between patient and society perspectives on
health outcomes [96]. See Box 8 for exemplars.
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Box 8 Exemplars on reporting item 3b elements
Example 1. Pre-planned adaptations and rationale; inferentially seamless
phase 2/3 AD
“The adaptive (inferentially) seamless phase II/III design is a novel
approach to drug development that combines phases II and III in a
single, two-stage study. The design is adaptive in that the wider choice
of doses included in stage 1 is narrowed down to the dose(s) of interest
to be evaluated in stage 2. The trial is a seamless experience for both in-
vestigators and patients in that there is no interruption of ongoing
study treatment between the two phases. Combining the dose-finding
and confirmatory phases of development into a single, uninterrupted
study has the advantages of speed, efficiency and flexibility [15, 17]…
The primary aim of stage 1 of the study was to determine the risk-
benefit of four doses of indacaterol (based on efficacy and safety results
in a pre-planned interim analysis) in order to select two doses to carry
forward into the second stage of the study.” [141]
Example 2. Analytical derivation of statistical information to guide
adaptations; population enrichment AD with SSR
Mehta et al. [95] detail formulae used to calculate the conditional power
to guide modification of the sample size or to enrich the patient
population at an interim analysis for both cutaneous and non-cutaneous
patients (full population) and only cutaneous patients (subpopulation) in
the supplementary material. In addition, the authors detail formulae
used to derive associated conditional powers and p-values used for
decision-making to claim evidence of benefit both at the interim and
final analysis (linked to item 12b).
Example 3. Pre-planned adaptations; 5-arm 2-stage AD allowing for regi-
men selection, early stopping for futility and SSR
“This randomized, placebo-controlled, double-blind, phase 2/3 trial had a
two-stage adaptive design, with selection of the propranolol regimen
(dose and duration) at the end of stage 1 (interim analysis) and further
evaluation of the selected regimen in stage 2 [63, 64]. Pre-specified pos-
sible adaptations to be made after the interim analysis, as outlined in
the protocol and statistical analysis plan (accessible via journal website),
were selection of one or two regimens, sample-size reassessment, and
non-binding stopping for futility.” [94]
Example 4. Type of AD; pre-planned adaptations and rationale; Bayesian
adaptive-enrichment AD allowing for enrichment and early stopping for fu-
tility or efficacy
“The DAWN trial was a multicenter, prospective, randomized, open-label
trial with a Bayesian adaptive–enrichment design and with blinded as-
sessment of endpoints [12]. The adaptive trial design allowed for a sam-
ple size ranging from 150 to 500 patients. During interim analyses, the
decision to stop or continue enrolment was based on a pre-specified
calculation of the probability that thrombectomy plus standard care
would be superior to standard care alone with respect to the first pri-
mary endpoint (described in the paper). The enrichment trial design
gave us the flexibility to identify whether the benefit of the trial inter-
vention was restricted to a subgroup of patients with relatively small in-
farct volumes at baseline. The interim analyses, which included patients
with available follow-up data at the time of the analysis, were pre-
specified to test for the futility, enrichment, and success of the trial.” [96]
See supplementary appendix via journal website (from page 39) for
details.
Example 5. Rationale; type of AD and pre-planned adaptations; information
to inform adaptations; information-based GSD
“Because little was known about the variability of LVMI changes in CKD
during the planning stage, we prospectively implemented an
information-based (group sequential) adaptive design that allowed sam-
ple size re-estimation when 50% of the data were collected [46, 156]. ”
[157] Pritchett et al. [46] provide details of the pre-planned adaptations
and statistical information used to inform SSR and efficacy early
stopping.
Example 6. Pre-planned adaptation and information for SSR
“To reassess the sample size estimate, the protocol specified that a
treatment-blinded interim assessment of the standard deviation (SD)
about the primary endpoint (change from baseline in total exercise
treadmill test duration at trough) would be performed when 231 or one
half of the planned completed study patients had been randomized
and followed up for 12 weeks. The recalculation of sample size, using
only blinded data, was adjusted based on the estimated SD of the
(Continued)
primary efficacy parameter (exercise duration at trough) from the aggre-
gate data… [158–160] ” [34]
CONSORT 2010 item 3b: Important changes to the
design or methods after trial commencement (such as
eligibility criteria), with reasons.
ACE item 3c (modification, renumbered): Important
changes to the design or methods after trial
commencement (such as eligibility criteria) outside the
scope of the pre-planned adaptive design features, with
reasons.
Explanation—Unplanned changes to certain aspects of
the design or methods in response to unexpected
circumstances that occur during the trial are common
and will need to be reported in AD randomised trials, as
in fixed design trials. This may include deviations from
pre-planned adaptations and decision rules [15, 66], as
well as changes to timing and frequency of interim ana-
lyses. Traditionally, unplanned changes with explanation
have been documented as protocol amendments and re-
ported as discussed in the CONSORT 2010 statement
[3, 4]. Unplanned changes, depending on what they are
and why they were made, may introduce bias and com-
promise trial credibility. Some unplanned changes may
render the planned adaptive statistical methods invalid
or may complicate interpretation of results [22]. It is
therefore essential for authors to detail important
changes that occurred outside the scope of the pre-
planned adaptations and to explain why deviations from
the planned adaptations were necessary. Furthermore, it
should be clarified whether unplanned changes were
made following access to key trial information such as
interim data seen by treatment group or interim results.
Such information will help readers assess potential
sources of bias and implications for the interpretation of
results. For ADs, it is essential to distinguish unplanned
changes from pre-planned adaptations (item 3b) [161].
See Box 9 for an exemplar.
Box 9 Exemplar on reporting item 3c elements
Example. Inferentially seamless phase 2/3 (5-arm 2-stage) AD allowing for
regimen selection, SSR and futility early stopping
Although this should ideally have been referenced in the main report,
Léauté-Labrèze et al. [94] (on pages 17–18 of supplementary material)
summarise important changes to the trial design including an
explanation and discussion of implications. These changes include a
reduction in the number of patients assigned to the placebo across
stages—randomisation was changed from 1:1:1:1:1 to 2:2:2:2:1 (each of
the 4 propranolol regimens: placebo) for stage 1 and from 1:1 to 2:1 for
stage 2 in favour of the selected regimen; revised complete or nearly
complete resolution success rates for certain treatment regimens. As a
result, total sample size was revised to 450 (excluding possible SSR); and
a slight increase in the number of patients (from 175 to 180) to be
recruited for the interim analysis.
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Section 6. Outcomes
CONSORT 2010 item 6a: Completely define pre-specified
primary and secondary outcome measures, including how
and when they were assessed.
ACE item 6a (modification): Completely define pre-
specified primary and secondary outcome measures, in-
cluding how and when they were assessed. Any other out-
come measures used to inform pre-planned adaptations
should be described with the rationale.
Comment—Authors should also refer to the
CONSORT 2010 statement [3, 4] for the original text
when applying this item.
Explanation—It is paramount to provide a detailed
description of pre-specified outcomes used to assess
clinical objectives including how and when they were
assessed. For operational feasibility, ADs often use out-
comes that can be observed quickly and easily to inform
pre-planned adaptations (adaptation outcomes). Thus, in
some situations, adaptations may be based on early ob-
served outcome(s) [162] that are believed to be inform-
ative for the primary outcome even though different
from the primary outcome. The adaptation outcome
(such as a surrogate, biomarker, or an intermediate out-
come) together with the primary outcome influences the
adaptation process, operating characteristics of the AD,
and interpretation and trustworthiness of trial results.
Despite many potential advantages of using early ob-
served outcomes to adapt a trial, they pose additional
risks of making misleading inferences if they are unreli-
able [163]. For example, a potentially beneficial treat-
ment could be wrongly discarded, an ineffective
treatment incorrectly declared effective or wrongly car-
ried forward for further testing, or the randomisation
updated based on unreliable information.
Authors should therefore clearly describe adaptation
outcomes similar to the description of pre-specified pri-
mary and secondary outcomes in the CONSORT 2010
statement [3, 4]. Authors are encouraged to provide a
clinical rationale supporting the use of an adaptation
outcome that is different to the primary outcome in
order to aid the clinical interpretation of results. For ex-
ample, evidence supporting that the adaptation outcome
can provide reliable information on the primary out-
come will suffice. See Box 10 for exemplars.
Box 10 Exemplars on reporting item 6a elements
Example 1. SSR; description of the adaptation and primary outcomes
“The primary endpoint is a composite of survival free of debilitating
stroke (modified Rankin score > 3) or the need for a pump exchange.
The short-term endpoint will be assessed at 6 months and the long-
term endpoint at 24 months (primary). Patients who are urgently trans-
planted due to a device complication before a pre-specified endpoint
will be considered study failures. All other transplants or device explants
due to myocardial recovery that occur before a pre-specified endpoint
will be considered study successes ... The adaptation was based on
(Continued)
interim short-term outcome rates.” [164]
Example 2. Seamless phase 2/3 Bayesian AD with treatment selection;
details of adaptation outcomes
“Four efficacy and safety measures were considered important for dose
selection based on early phase dulaglutide data: HbA1c, weight, pulse
rate and diastolic blood pressure (DBP) [165]. These measures were used
to define criteria for dose selection. The selected dulaglutide dose(s) had
to have a mean change of ≤ + 5 beats per minute (bpm) for PR
and≤ + 2mmHg for DBP relative to placebo at 26 weeks. In addition, if
a dose was weight neutral versus placebo, it had to show HbA1c
reduction ≥1.0% and/or be superior to sitagliptin at 52 weeks. If a dose
reduced weight relative to placebo ≥2.5 kg, then non-inferiority to sita-
gliptin would be acceptable. A clinical utility index was incorporated in
the algorithm to facilitate adaptive randomization and dose selection
[154, 166] based on the same parameters used to define dose-selection
criteria described above (not shown here).” [93]
Example 3. Seamless phase 2/3 AD with treatment selection; details of
adaptation outcomes
“For the dose selection, the joint primary efficacy outcomes were the
trough FEV1 on Day 15 (mean of measurements at 23 h 10 min and 23 h
45 min after the morning dose on Day 14) and standardized (average)
FEV1 area under the curve (AUC) between 1 and 4 h after the morning
dose on Day 14 (FEV1AUC1–4h), for the treatment comparisons detailed
below (not shown here).” [141]
Example 4. MAMS AD; adaptation rationale (part of item 3b); rationale for
adaption outcome different from the primary outcome; description of the
adaptation and primary outcomes
“This seamless phase 2/3 design starts with several trial arms and uses
an intermediate outcome to adaptively focus accrual away from the less
encouraging research arms, continuing accrual only with the more
active interventions. The definitive primary outcome of the STAMPEDE
trial is overall survival (defined as time from randomisation to death
from any cause). The intermediate primary outcome is failure-free sur-
vival (FFS) defined as the first of: PSA failure (PSA > 4 ng/mL and PSA >
50% above nadir); local progression; nodal progression; progression of
existing metastases or development of new metastases; or death from
prostate cancer. FFS is used as a screening method for activity on the
assumption that any treatment that shows an advantage in overall sur-
vival will probably show an advantage in FFS beforehand, and that a
survival advantage is unlikely if an advantage in FFS is not seen. There-
fore, FFS can be used to triage treatments that are unlikely to be of suffi-
cient benefit. It is not assumed that FFS is a surrogate for overall
survival; an advantage in FFS might not necessarily translate into a sur-
vival advantage.” [167]
CONSORT 2010 item 6b: Any changes to trial outcomes
after the trial commenced, with reasons.
ACE item 6b (modification): Any unplanned changes to
trial outcomes after the trial commenced, with reasons.
Comment—Authors may wish to cross-reference the
CONSORT 2010 statement [3, 4] for background details.
Explanation—Outcome reporting bias occurs when
the selection of outcomes to report is influenced by the
nature and direction of results. The prevalence of
outcome reporting bias in medical research is well
documented: discrepancies between pre-specified out-
comes in protocols or registries and those published in
reports [12, 168–171]; outcomes that portray favourable
beneficial effects of treatments and safety profiles being
more likely to be reported [169]; some pre-specified pri-
mary or secondary outcomes modified or switched after
trial commencement [170]. Changes to trial outcomes
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may also include changes to how outcomes were
assessed or measured, when they were assessed, or the
order of importance to address objectives [171].
Sometimes when planning trials, there is huge
uncertainty around the magnitude of treatment effects
on potential outcomes viewed acceptable as primary
endpoints [105, 171]. As a result, although uncommon, a
pre-planned adaptation could include the choice of the
primary endpoints or hypotheses for assessing the
benefit-risk ratio. In such circumstances, the adaptive
strategy should be clearly described as a pre-planned
adaptation (item 3b). Authors should clearly report any
additional changes to outcomes outside the scope of the
pre-specified adaptations including an explanation of
why such changes occurred in line with the CONSORT
2010 statement. This will enable readers to distinguish
pre-planned trial adaptations of outcomes from un-
planned changes, thereby allowing them to judge out-
come reporting bias. See Box 11 for an exemplar.
Box 11 Exemplar on reporting item 6b
Example. Bayesian adaptive-enrichment AD; unplanned change from a sec-
ondary to a co-primary outcome, rationale, and when it happened
“The second primary endpoint was the rate of functional independence
(defined as a score of 0, 1, or 2 on the modified Rankin scale) at 90 days.
This endpoint was changed from a secondary endpoint to a co-primary
endpoint at the request of the Food and Drug Administration at 30
months after the start of the trial, when the trial was still blinded.” [96]
Section 7. Sample size and operating characteristics
CONSORT 2010 item 7a: How sample size was
determined.
ACE item 7a (modification): How sample size and
operating characteristics were determined.
Comments—This section heading was modified to
reflect additional operating characteristics that may be
required for some ADs in addition to the sample size.
Items 3b, 7a, 7b, and 12b are connected so they should
be cross-referenced when reporting.
Explanation—Operating characteristics, which relate to
the statistical behaviour of a design, should be tailored to
address trial objectives and hypotheses, factoring in
logistical, ethical, and clinical considerations. These may
encompass the maximum sample size, expected sample
sizes under certain scenarios, probabilities of identifying
beneficial treatments if they exist, and probabilities of
making false positive claims of evidence [172, 173].
Specifically, the predetermined sample size for ADs is
influenced, among other things, by:
1. Type and scope of adaptations considered (item 3b);
2. Decision-making criteria used to inform adaptations
(item 7b);
3. Criteria for claiming overall evidence (such as based
on the probability of the treatment effect being
above a certain value, targeted treatment effect of
interest, and threshold for statistical significance
[174, 175]);
4. Timing and frequency of the adaptations (item 7b);
5. Type of primary outcome(s) (item 6a) and nuisance
parameters (such as outcome variance);
6. Method for claiming evidence on multiple key
hypotheses (part of item 12b);
7. Desired operating characteristics (see Box 2), such
as statistical power and an acceptable level of
making a false positive claim of benefit;
8. Adaptive statistical methods used for analysis (item
12b);
9. Statistical framework (frequentist or Bayesian) used
to design and analyse the trial.
Information that guided estimation of sample size(s),
including operating characteristics of the considered AD,
should be described sufficiently to enable readers to
reproduce the sample size calculation. The assumptions
made concerning design parameters should be clearly
stated and supported with evidence if possible. Any
constraints imposed (for example, due to limited trial
population) should be stated. It is good scientific practice
to reference the statistical tools used (such as statistical
software, program, or code) and to describe the use
of statistical simulations when relevant (see item 24b
discussion).
In a situation where changing the sample size is a pre-
planned adaptation (item 3b), authors should report the
initial sample sizes (at interim analyses before the ex-
pected change in sample size) and the maximum allow-
able sample size per group and in total if applicable. The
planned sample sizes (or expected numbers of events for
time-to-event data) at each interim analysis and final
analysis should be reported by treatment group and
overall. The timing of interim analyses can be specified
as a fraction of information gathered rather than sample
size. See Box 12 for exemplars.
Box 12 Exemplars on reporting item 7a elements
Example 1. MAMS AD; assumptions and adaptive methods; approach for
claiming evidence or informing adaptations; statistical program
“The primary response (outcome) from each patient is the difference
between the baseline HOMA-IR score and their HOMA-IR score at 24
weeks. The sample size calculation is based on a one-sided type I error
of 5% and a power of 90%. If there is no difference between the mean
response on any treatment and that on control, then a probability of
0.05 is set for the risk of erroneously ending the study with a recom-
mendation that any treatment be tested further. For the power, we
adopt a generalisation of this power requirement to multiple active
treatments due to Dunnett [176]. Effect sizes are specified as the per-
centage chance of a patient on active treatment achieving a greater re-
duction in HOMA-IR score than a patient on control as this specification
does not require knowledge of the common SD, σ. The requirement is
that, if a patient on the best active dose has a 65% chance of a better
response than a patient on control, while patients on the other two ac-
tive treatments have a 55% chance of showing a better response than a
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patient on control, then the best active dose should be recommended
for further testing with 90% probability. A 55% chance of achieving a
better response on active dose relative to control corresponds to a re-
duction in mean HOMA-IR score of about a sixth of an SD (0.178σ),
while the clinically relevant effect of 65% corresponds to a reduction of
about half an SD (0.545σ). The critical values for recommending that a
treatment is taken to further testing at the interim and final analyses
(2.782 and 2.086) have been chosen to guarantee these properties using
a method described by Magirr et al. [177], generalising the approach of
Whitehead and Jaki [178]. The maximum sample size of this study is 336
evaluable patients (84 per arm), although the use of the interim analysis
may change the required sample size. The study will recruit additional
patients to account for an anticipated 10% dropout rate (giving a total
sample size of 370). An interim analysis will take place once the primary
endpoint is available for at least 42 patients on each arm (i.e., total of
168, half of the planned maximum of 336 patients). Sample size calcula-
tion was performed using the MAMS package in R [179].” [53]
Example 2. 3-arm 2-stage AD with dose selection; group sequential ap-
proach; assumptions; adaptation decision-making criteria; stage 1 and 2
sample sizes; use of simulations
“Sample size calculations are based on the primary efficacy variable
(composite of all-cause death or new MI through day 7), with the fol-
lowing assumptions: an event rate in the control group of 5.0%, based
on event rates from the phase II study (24); a relative risk reduction
(RRR) of 25%; a binomial 1-sided (α = 0.025) superiority test for the com-
parison of 2 proportions with 88% power; and a 2-stage adaptive design
with one interim analysis at the end of stage 1 data (35% information
fraction) to select 1 otamixaban dose for continuation of the study at
stage 2. Selection of the dose for continuation was based on the com-
posite end point of all-cause death, Myocardial Infarction (MI), throm-
botic complication, and the composite of Thrombosis in Myocardial
Infarction (TIMI) major bleeding through day 7, with an assumed prob-
ability for selecting the “best” dose according to the primary endpoint
(r = 0.6), a group sequential approach with futility boundary of relative
risk of otamixaban versus UFH plus eptifibatide ≥1.0, and efficacy
boundary based on agamma (− 10) α spending function [180]. Based on
the above assumptions, simulations (part of item 24b, see supplementary
material) showed that 13,220 patients (a total of 5625 per group for the
2 remaining arms for the final analysis) are needed for this study.” [181]
See Fig. 1.
CONSORT 2010 item 7b: When applicable, explanation
of any interim analyses and stopping guidelines.
ACE item 7b (replacement): Pre-planned interim
decision-making criteria to guide the trial adaptation
process; whether decision-making criteria were binding or
non-binding; pre-planned and actual timing and fre-
quency of interim data looks to inform trial adaptations.
Comments—This item is a replacement so when
reporting, the CONSORT 2010 [3] item 7b content
should be ignored. Items 7b and 8b overlap, but we
intentionally reserved item 8b specifically to enhance
complete reporting of ADs with randomisation updates
as a pre-planned adaptation. Reporting of these items is
also connected to items 3b and 12b.
Explanation—Transparency and complete reporting of
pre-planned decision-making criteria (Box 2) and how
overall evidence is claimed are essential as they influence
operating characteristics of the AD, credibility of the
trial, and clinical interpretation of findings [22, 32, 183].
A key feature of an AD is that interim decisions about
the course of the trial are informed by observed interim
data (element of item 3b) at one or more interim
analyses guided by decision rules describing how and
when the proposed adaptations will be activated (pre-
planned adaptive decision-making criteria). Decision
rules, as defined in Box 2, may include, but are not lim-
ited to, rules for making adaptations described in Table
1. Decision rules are often constructed with input of key
stakeholders (such as clinical investigators, statisticians,
patient groups, health economists, and regulators) [184].
For example, statistical methods for formulating early
stopping decision rules of a trial or treatment group(s)
exist [47, 48, 185–188].
Decision boundaries (for example, stopping boundaries),
pre-specified limits or parameters used to determine adap-
tations to be made, and criteria for claiming overall evi-
dence of benefit and/or harm (at an interim or final
analysis) should be clearly stated. These are influenced by
statistical information used to inform adaptations (item
3b). Decision trees or algorithms can aid the representa-
tion of complex adaptive decision-making criteria.
Allowing for trial adaptations too early in a trial with
inadequate information severely undermines robustness
of adaptive decision-making criteria and trustworthiness
of trial results [189, 190]. Furthermore, methods and re-
sults can only be reproducible when timing and fre-
quency of interim analyses are adequately described.
Therefore, authors should detail when and how often
the interim analyses were planned to be implemented.
The planned timing can be described in terms of infor-
mation such as interim sample size or number of events
relative to the maximum sample size or maximum num-
ber of events, respectively. For example, in circumstances
when the pre-planned and actual timing or/and frequency
of the interim analyses differ, reports should clearly state
what actually happened (item 3c).
Clarification should be made on whether decision
rules were binding or non-binding to help assess impli-
cations in the case when they were overruled or ignored.
For example, when a binding futility boundary is over-
ruled and a trial is continued, this would lead to a type I
error inflation. Non-binding decision rules are those that
can be overruled without having a negative effect on the
control of the type I error rate. Use of non-binding futil-
ity boundaries is often advised [51]. See Box 13 for
exemplars.
Box 13 Exemplars on reporting item 7b elements
Example 1. 2-arm 2-stage AD with options for early stopping for futility or
superiority and to increase the sample size; binding stopping rules
“To calculate the number of patients needed to meet the primary
endpoint, we expected a 3-year overall survival rate of 25% in the group
assigned to preoperative chemotherapy (arm A) (based on two previous
trials [191, 192]). In comparison, an increase of 10% (up to 35%) was
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anticipated by preoperative CRT. Using the log-rank test (one-sided at
this point) at a significance level of 5%, we calculated to include 197 pa-
tients per group to ensure a power of 80%. In the first stage of the
planned two-stage adaptive design [193], the study was planned to be
continued on the basis of a new calculation of patients needed if the
comparison of patient groups will be 0.0233 < p1 < 0.5. Otherwise, the
study may be closed for superiority (p1 < 0.0233) or shall be closed for
futility (p1 ≥ 0.5). There was no maximum sample size cap and stopping
rules were binding.” [194] Values p1 and p2 are p-values derived from in-
dependent stage 1 and stage 2 data, respectively. Evidence of benefit
will be claimed if the overall two-stage p-value derived from p1 and p2
is ≤0.05.
Example 2. Timing and frequency of interim analyses; planned stopping
boundaries for superiority and futility. See Table 4
Example 3. Planned timing and frequency of interim analyses; pre-specified
dose selection rules for an inferentially seamless phase 2/3 (7-arm 2-stage)
AD
“The interim analysis was pre-planned for when at least 110 patients per
group (770 total) had completed at least 2 weeks of treatment. The dose
selection guidelines were based on efficacy and safety. The mean effect
of each indacaterol dose versus placebo was judged against pre-set effi-
cacy reference criteria for trough FEV1 and FEV1AUC1–4h. For trough
FEV1, the reference efficacy criterion was the highest value of: (a) the dif-
ference between tiotropium and placebo, (b) the difference between
formoterol and placebo, or (c) 120 mL (regarded as the minimum clinic-
ally important difference). For standardized FEV1AUC1–4h, the reference
efficacy criterion was the highest value of: (a) the difference between
tiotropium and placebo or (b) the difference between formoterol and
placebo. If more than one indacaterol dose exceeded both the efficacy
criteria, the lowest effective dose plus the next higher dose were to be
selected. Data on peak FEV1, % change in FEV1, and FVC were also sup-
plied to the DMC for possible consideration, but these measures were
not part of the formal dose selection process and are not presented
here. The DMC also took into consideration any safety signals observed
in any treatment arm.” [141]
Example 4. Timing and frequency of interim analyses; decision-making cri-
teria for population enrichment and sample size increase
“Cohort 1 will enrol a total of 120 patients and followed them until 60
PFS events are obtained. At an interim analysis based on the first 40 PFS
events, an independent data monitoring committee will compare the
conditional power for the full population (CPF) and the conditional
power for the cutaneous subpopulation (CPS). The formulae for these
conditional powers are given in the supplementary appendix (part of
item 3b, example 2, Box 8). (a) If CPF < 0.3 and CPS < 0.5, the results are in
the unfavourable zone; the trial will enrol 70 patients to cohort 2 and
follow them until 35 PFS events are obtained (then test effect in the full
population). (b) If CPF < 0.3 and CPS > 0.5, the results are in the
enrichment zone; the trial will enrol 160 patients with cutaneous disease
(subpopulation) to cohort 2 and follow them until 110 PFS events have
been obtained from the combined patients in both cohorts with
cutaneous disease only (then test effect only in the cutaneous
subpopulation). (c) If 0.3≤ CPF ≤ 0.95, the results are in the promising
zone (so increase sample size); the trial will enrol 220 patients (full
population) to cohort 2 and follow them up until 110 PFS events are
obtained (then test effect in the full population). (d) If CPF > 0.95, the
results are in the favourable zone; the trial will enrol 70 patients to
cohort 2 and follow them until 35 PFS events are obtained (then test
effect in full population).” [95] See Fig. 2 of Mehta et al. [95] for a
decision-making tree.
Example 5. Bayesian GSD with futility early stopping; frequency and timing
of interim analyses; adaptation decision-making criteria; criteria for claim-
ing treatment benefit
“We adopted a group-sequential Bayesian design [182] with three
stages, of 40 patients each (in total), and two interim analyses after 40
and 80 randomised participants, and a final analysis after a maximum of
120 randomised participants. We decided that the trial should be
stopped early if there is a high (posterior) probability (90% or greater)
(item 3b details) that the 90-day survival odds ratio (OR) falls below 1
(i.e. REBOA is harmful) at the first or second interim analysis. REBOA will
(Continued)
be declared “successful” if the probability that the 90-day survival OR ex-
ceeds 1 at the final analysis is 95% or greater.” [196]
Additional examples on the use of non-binding futility
boundaries and a cap on sample size following SSR and
treatment selection are given in Additional file 2.
Section 8. Randomisation (Sequence generation)
CONSORT 2010 item 8b: Type of randomisation; details
of any restriction (such as blocking and block size).
ACE item 8b (modification): Type of randomisation;
details of any restriction (such as blocking and block
size); any changes to the allocation rule after trial
adaptation decisions; any pre-planned allocation rule or
algorithm to update randomisation with timing and fre-
quency of updates.
Comments—In applying this item, the reporting of
randomisation aspects before activation of trial adaptations
must adhere to CONSORT 2010 items 8a and 8b. This
E&E document only addresses additional randomisation
aspects that are essential when reporting any AD where
the randomisation allocation changes. Note that the
contents of extension items 7b and 8b overlap.
Explanation—In AD randomised trials, the allocation
ratio(s) may remain fixed throughout or change during
the trial as a consequence of pre-planned adaptations
(for example, when modifying randomisation to favour
treatments more likely to show benefits, after treatment
selection, or upon introduction of a new arm to an on-
going trial) [69]. Unplanned changes may also change al-
location ratios (for example, after early stopping of a
treatment arm due to unforeseeable harms).
This reporting item is particularly important for
response-adaptive randomisation (RAR) ADs as several
factors influence their efficiency and operating charac-
teristics, which in turn influence the trustworthiness of
results and necessitate adequate reporting [13, 182, 197–
199]. For RAR ADs, authors should therefore detail the
pre-planned:
a) Burn-in period before activating randomisation
updates, including the period when the control
group allocation ratio was fixed;
b) Type of randomisation method with allocation
ratios per group during the burn-in period as de-
tailed in the standard CONSORT 2010 item 8b;
c) Method or algorithm used to adapt or modify the
randomisation allocations after the burn-in period;
d) Information used to inform the adaptive
randomisation algorithm and how it was derived
(item 3b). Specifically, when a Bayesian RAR is
used, we encourage authors to provide details of
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statistical models and rationale for the prior
distribution chosen;
e) Frequency of updating the allocation ratio (for
example, after accrual of a certain number of
participants with outcome data or defined regular
time period) and;
f) Adaptive decision-making criteria to declare early
evidence in favour or against certain treatment
groups (part of item 7b).
In addition, any envisaged changes to the allocation
ratio as a consequence of other trial adaptations (for
example, early stopping of an arm or addition of a new
arm) should be stated. See Box 14 for exemplars.
Box 14 Exemplars on reporting item 8b elements
Example 1. Pre-planned changes to allocation ratios as a consequence of
treatment selection or/and sample size increase
“All new patients recruited after the conclusions of the interim analysis
are made, will be randomised in a (2:) 2: 1 ratio to the selected
regimen(s) of propranolol or placebo until a total of (100:)100: 50
patients (or more in the case where a sample size increase is
recommended) have been randomised over the two stages of the
study.” [94] Extracted from supplementary material. (2:) and (100:) are
only applicable if the second best regimen is selected at stage 1.
Example 2. Bayesian RAR; pre-planned algorithm to update allocation ra-
tios; frequency of updates (after every participant);no burn-in period; period
of a fixed control allocation ratio; information that informed adaptation;
decision-making criteria for dropping treatments (part of item 7b)
See Additional file 3 as extracted from Giles et al. [67]
Example 3. Bayesian RAR; burn-in period; fixed control allocation ratio; de-
tails of adaptive randomisation including additional adaptations and
decision-making criteria (part of item 7b); derivation of statistical quantities;
details of Bayesian models and prior distribution with rationale
“…eligible patients were randomized on day 1 to treatment with
placebo or neublastin 50, 150, 400, 800, or 1200 mg/kg, administered by
intravenous injection on days 1, 3, and 5. The first 35 patients were
randomized in a 2:1:1:1:1:1 ratio to placebo and each of the 5 active
doses (randomisation method required) (i.e., 10 patients in the placebo
group and 5 for each dose of active treatment). Subsequently, 2 of
every 7 enrolled patients were assigned to placebo. Interim data
evaluations of pain (AGPI) and pruritus questionnaire data (proportion of
patients who reported ‘the itch is severe enough to cause major
problems for me’ on an Itch Impact Questionnaire) were used to update
the allocation probability according to a Bayesian algorithm for adaptive
allocation and to assess efficacy and futility criteria for early stopping of
enrolment (Fig. 1 [not shown here]). Interim evaluations and updates to
the allocation probabilities were performed weekly. Enrolment was to
be stopped early after ≥50 patients had been followed for 4 weeks if
either the efficacy criterion (> 80% probability that the maximum utility
dose reduces the pain score by ≥1.5 points more than the placebo) or
the futility criterion (< 45% probability that the maximum utility dose
Fig. 1 Adapted from Steg et al. [182]
Table 4 Stopping boundaries
Interim
analysis
Number of
primary
outcome
events
(information
fraction)
Stopping boundaries
Superiority Futility
Hazard ratio P-value Hazard ratio P-value
1 800 (50%) < 0.768 < 0.0002 > 0.979 > 0.758
2 1200 (75%) < 0.806 < 0.0002 > 0.931 > 0.216
Final 1600 (100%) < 0.906 < 0.0500
Adapted from Pocock et al. [195]; primary outcome events are cardiovascular
deaths, myocardial infarction, or ischaemic stroke
Dimairo et al. Trials          (2020) 21:528 Page 15 of 34
(Continued)
reduces pain more than the placebo) was met.” [140] Details of
statistical models used—including computation of posterior quantities;
prior distribution with rationale; generation of the utility function; and
weighting of randomisation probabilities—are accessible via a weblink
provided (https://links.lww.com/PAIN/A433).
Section 11. Randomisation (Blinding)
ACE item 11c (new): Measures to safeguard the
confidentiality of interim information and minimise
potential operational bias during the trial.
Explanation—Preventing or minimising bias is central
for robust evaluation of the beneficial and harmful
effects of interventions. Analysis of accumulating trial
data brings challenges regarding how knowledge or
leakage of information, or mere speculation about
interim treatment effects, may influence behaviour of
key stakeholders involved in the conduct of the trial [22,
122, 200]. Such behavioural changes may include
differential clinical management; reporting of harmful
effects; clinical assessment of outcomes; and decision-
making to favour one treatment group over the other.
Inconsistencies in trial conduct before and after adapta-
tions have wide implications that may affect trial validity
and integrity [22]. For example, use of statistical
methods that combine data across stages may become
questionable or may make overall results uninterpret-
able. AD randomised trials whose integrity was severely
compromised by disclosure of interim results have
resulted in regulators questioning the credibility of con-
clusions [201, 202]. Most AD randomised trials, 76%
(52/68) [45] and 60% (151/251) [112], did not disclose
methods to minimise potential operational bias during
interim analyses. The seriousness of this potential risk
will depend on various trial characteristics, and the pur-
pose of having disclosure is to enable readers to judge
the risk of potential sources of bias, and thus judge how
trustworthy they can assume results to be.
The literature covers processes and procedures which
could be considered by researchers to preserve con-
fidentiality of interim results to minimise potential
operational bias [41, 123, 203]. There is no universal
approach that suits every situation due to factors such as
feasibility; nature of the trial; and available resources and
infrastructure. Some authors discuss roles and activities
of independent committees in adaptive decision-making
processes and control mechanisms for limiting access to
interim information [203–205].
Description of the process and procedures put in place
to minimise the potential introduction of operational
bias related to interim analyses and decision-making to
inform adaptations is essential [22, 125, 203]. Specific-
ally, authors should give consideration to:
a) Who recommended or made adaptation decisions.
The roles of the sponsor or funder, clinical
investigators, and trial monitoring committees (for
example, independent data monitoring committee
Fig. 2 Redrawn from Gilson et al. [260] Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://
creativecommons.org/licenses/by/4.0/). No changes to the original figure were made
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or dedicated committee for adaptation) in the
decision-making process should be clearly stated;
b) Who had access to interim data and performed
interim analyses;
c) Safeguards which were in place to maintain
confidentiality (for example, how the interim results
were communicated and to whom and when).
See Box 15 for exemplars.
Box 15 Exemplars on reporting item 11c elements
Example 1. Inferentially seamless phase 2/3 AD
“The interim analysis was carried out by an independent statistician
(from ClinResearch GmbH, Köln, Germany), who was the only person
outside the Data Monitoring Committee (DMC) with access to the semi-
blinded randomization (sic) codes (treatment groups identified by letters
A to G). This statistician functioned independently of the investigators,
the sponsor’s clinical trial team members and the team that produced
statistical programming for the interim analysis (DATAMAP GmbH, Frei-
burg, Germany). The independent statistician was responsible for all ana-
lyses of efficacy and safety data for the interim analysis. The DMC was
given semi-blinded results with treatment groups identified by the let-
ters A to G, with separate decodes sealed in an envelope to be opened
for decision-making. The personnel involved in the continuing clinical
study were told which two doses had been selected, but study blinding
remained in place and the results of the interim analysis were not com-
municated. No information on the effects of the indacaterol doses (in-
cluding the two selected) was communicated outside the DMC.” [141]
Example 2. Bayesian inferentially seamless phase 2/3 AD with RAR
“An independent Data Monitoring Committee (DMC) external to Lilly
provided oversight of the implementation of the adaptive algorithm
and monitored study safety. The DMC fulfilled this role during the dose-
finding portion, and continued monitoring after dose selection until an
interim database lock at 52 weeks, at which time the study was un-
blinded to assess the primary objectives. Sites and patients continued to
be blinded to the treatment allocation until the completion of the
study. The DMC was not allowed to intervene with the design opera-
tions. A Lilly Internal Review Committee (IRC), independent of the study
team, would meet if the DMC recommended the study to be modified.
The role of the IRC was to make the final decision regarding the DMC’s
recommendation. The external Statistical Analysis Center (SAC) per-
formed all interim data analyses for the DMC, evaluated the decision
rules and provided the randomization updates for the adaptive algo-
rithm. The DMC chair and the lead SAC statistician reviewed these (in-
terim) reports and were tasked to convene an unscheduled DMC
meeting if an issue was identified with the algorithm or the decision
point was triggered.” [93]
Example 3. Inferentially seamless phase 2/3 AD with treatment selection,
SSR, and non-binding futility stopping
“Following the interim analysis of the data and the review of initial
study hypotheses, the committee (IDMC) chairman will recommend in
writing to the sponsor whether none, one or two regimen(s) of
propranolol is (are) considered to be the ‘best’ (the most efficacious out
of all regimens with a good safety profile) for further study in stage two
of the design. The second ‘best’ regimen will only be chosen for further
study along with the ‘best’ regimen if the first stage of the study
suggests that recruitment in the second stage will be too compromised
by the fact that 1 in 3 patients are assigned to placebo. The IDMC will
not reveal the exact sample size increase in the recommendation letter
in order to avoid potential sources of bias (only the independent
statistician, the randomisation team and the IP suppliers will be
informed of the actual sample size increase). Any safety concerns will
also be raised in the IDMC recommendation letter. The chairman will
ensure that the recommendations do not unnecessarily unblind the
study. In the case where the sponsor decides to continue the study, the
independent statistician will communicate to the randomisation team
which regimen(s) is (are) to be carried forward.” [94] Extracted from
supplementary material.
Section 12. Statistical methods
CONSORT 2010 item 12a: Statistical methods used to
compare groups for primary and secondary outcomes.
ACE item 12a (modification): Statistical methods used
to compare groups for primary and secondary outcomes,
and any other outcomes used to make pre-planned
adaptations.
Comment—This item should be applied with reference
to the detailed discussion in the CONSORT 2010
statement [3, 4].
Explanation—The CONSORT 2010 statement [3, 4]
addresses the importance of detailing statistical methods
to analyse primary and secondary outcomes at the end
of the trial. This ACE modified item extends this to
require similar description to be made of statistical
methods used for interim analyses. Furthermore, statistical
methods used to analyse any other adaptation outcomes
(item 6) should be detailed to enhance reproducibility of
the adaptation process and results. Authors should focus
on complete description of statistical models and aspects
of the estimand of interest [206, 207] consistent with
stated objectives and hypotheses (item 2b) and pre-
planned adaptations (item 3b).
For Bayesian ADs, item 12b (paragraph 6) describes
similar information that should be reported for Bayesian
methods.
See Box 16 for exemplars.
Box 16 Exemplars on reporting item 12a elements
Example 1. Frequentist AD
Authors are referred to the CONSORT 2010 statement [3, 4] for
examples.
Example 2. 2-stage Bayesian biomarker-based AD with RAR
In a methods paper, Gu et al. [208] detail Bayesian logistic regression
models for evaluating treatment and marker effects at the end of stage
1 and 2 using non-informative normal priors during RAR and futility
early stopping decisions. Strategies for variable selection and model
building at the end of stage 1 to identify further important biomarkers
for use in RAR of stage 2 patients are described (part of item 3b), includ-
ing a shrinkage prior used for biomarker selection with rationale.
ACE item 12b (new): For the implemented adaptive
design features, statistical methods used to estimate
treatment effects for key endpoints and to make inferences.
Comments—Note that items 7a and 12b are connected.
Key endpoints are all primary endpoints as well as other
endpoints considered highly important, for example, an
endpoint used for adaptation.
Explanation—A goal of every trial is to provide
reliable estimates of the treatment effect for assessing
benefits and risks to reach correct conclusions. Several
statistical issues may arise when using an AD depending
on its type and the scope of adaptations, the adaptive
decision-making criteria and whether frequentist or
Bayesian methods are used to design and analyse the
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trial [22]. Conventional estimates of treatment effect
based on fixed design methods may be unreliable when
applied to ADs (for example, may exaggerate the patient
benefit) [92, 209–213]. Precision around the estimated
treatment effects may be incorrect (for example, the
width of confidence intervals may be incorrect). Other
methods available to summarise the level of evidence in
hypothesis testing (for example, p-values) may give dif-
ferent answers. Some factors and conditions that influ-
ence the magnitude of estimation bias have been
investigated and there are circumstances when it may
not be of concern [209, 214–218]. Secondary analyses
(for example, health economic evaluation) may also be
affected if appropriate adjustments are not made [219,
220]. Cameron et al. [221] discuss methodological chal-
lenges in performing network meta-analysis when com-
bining evidence from randomised trials with ADs and
fixed designs. Statistical methods for estimating the
treatment effect and its precision exist for some ADs
[64, 222–231] and implementation tools are being devel-
oped [78, 232–234]. However, these methods are rarely
used or reported and the implications are unclear [45,
209, 235]. Debate and research on inference for some
ADs with complex adaptations is ongoing.
In addition to statistical methods for comparing
outcomes between groups (item 12a), we specifically
encourage authors to clearly describe statistical methods
used to estimate measures of treatment effects with
associated uncertainty (for example, confidence or
credible intervals) and p-value (when appropriate); refer-
encing relevant literature is sufficient. When conven-
tional or naïve estimators derived from fixed design
methods are used, it should be clearly stated. In situa-
tions where statistical simulations were used to either
explore the extent of bias in estimation of the treatment
effects (such as [181, 236]) or operating characteristics,
it is good practice to mention this and provide support-
ing evidence (item 24c).
ADs tend to increase the risk of making misleading or
unjustified claims of treatments effects if traditional
methods that ignore trial adaptations are used. In general,
this arises when selecting one or more hypothesis test
results from a possible list in order to claim evidence of
the desired conclusion. For instance, the risks may
increase by testing the same hypothesis several times
(for example, at interim and final analyses), hypothesis
testing of multiple treatment comparisons, selecting an
appropriate population from multiple target populations,
adapting key outcomes, or a combination of these [22]. A
variety of adaptive statistical methods exist for controlling
specific operating characteristics of the design (for
example, type I error rate, power) depending on the
nature of the repeated testing of hypotheses [47, 57, 58,
78, 193, 237–242].
Authors should therefore state operating characteristics
of the design that have been controlled and details of
statistical methods used. The need for controlling a
specific type of operating characteristic (for example,
pairwise or familywise type I error rate) is context
dependent (for example, based on regulatory con-
siderations, objectives and setting) so clarification is
encouraged to help interpretation. How evidence of
benefit and/or risk is claimed (part of item 7a) and
hypotheses being tested (item 2b) should be clear. In
situations where statistical simulations were used, we
encourage authors to provide a report, where possible
(item 24b).
When data or statistical tests across independent stages
are combined to make statistical inference, authors should
clearly describe the combination test method (for
example, Fisher’s combination method, inverse normal
method or conditional error function) [193, 240, 241, 243,
244] and weights used for each stage (when not obvious).
This information is important because different methods
and weights may produce results that lead to different
conclusions. Bauer and Einfalt [107] found low reporting
quality of these methods.
Brard et al. [245] found evidence of poor reporting of
Bayesian methods. To address this, when a Bayesian AD is
used, authors should detail the model used for analysis to
estimate the posterior probability distribution; the prior
distribution used and rationale for its choice; whether the
prior was updated in light of interim data and how; and
clarify the stages when the prior information was used
(interim or/and final analysis). If an informative prior was
used, the source of data to inform this prior should be
disclosed where applicable. Of note, part of the Bayesian
community argue that it is not principled to control
frequentist operating characteristics in Bayesian ADs
[246], although these can be computed and presented [22,
154, 247].
Typically, ADs require quickly observed adaptation
outcomes relative to the expected length of the trial. In
some ADs, randomised participants who have received
the treatment may not have their outcome data available
at the interim analysis (referred to as overrunning
participants) for various reasons [248]. These delayed
responses may pose ethical dilemmas depending on the
adaptive decisions taken, present logistical challenges, or
diminish the efficiency of the AD depending on their
prevalence and the objective of the adaptations [201]. It
is therefore useful for readers to understand how
overrunning participants were dealt with at interim
analyses especially after a terminal adaptation decision
(for example, when a trial or treatment groups were
stopped early for efficacy or futility). If outcome data of
overrunning participants were collected, a description
should be given of how these data were analysed and
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combined with interim results after the last interim
decision was made. Some formal statistical methods to
deal with accrued data from overrunning participants
have been proposed [249].
See Box 17 for exemplars.
Box 17 Exemplars on reporting item 12 elements
Example 1. GSD; statistical method for estimating treatment effects
“Stagewise ordering was used to compute the unbiased median
estimate and confidence limits for the prognosis-group-adjusted hazard
rates [250]. ” [251]
Example 2. Inferentially seamless (4-arm 2-stage) AD with dose selection;
statistical methods for controlling operating characteristics
“…the power of the study ranged from 71 to > 91% to detect a
treatment difference at a one-sided α of 0.025 when the underlying re-
sponse rate of ≥1 of the crofelemer dose groups exceeded placebo by
20%. The clinical response of 20% was based on an estimated response
rate of 55% in crofelemer and 35% in placebo during the 4-week
placebo-controlled assessment period.… For the primary endpoint, the
test for comparing the placebo and treatment arms reflected the fact
that data were gathered in an adaptive fashion and controlled for the
possibility of an increased Type I error rate. Using the methods of Posch
and Bauer [64], as agreed upon during the special protocol assessment
process, a p-value was obtained for comparison of each dose to the pla-
cebo arm from the stage I data, and an additional p-value was obtained
for comparison of the optimal dose to the placebo arm from the inde-
pendent data gathered in stage II. For the final primary analysis, the p-
values from the first and second stages were combined by the inverse
normal weighting combination function, and a closed testing procedure
was implemented to test the null hypothesis using the methods of
Posch and Bauer [64], based on the original work of Bauer and Kieser
[65]. This closed test controlled the experiment-wise error rate for this 2-
stage adaptive design at a one-sided α of 0.025.” [252] Extracted from
appendix material.
Example 3. 3-arm 2-stage group-sequential AD with treatment selection;
combination test method; multiplicity adjustments; statistical method for
estimating treatment effects
“The proposed closed testing procedure will combine weighted inverse
normal combination tests using pre-defined fixed weights, the closed
testing principle [64, 253, 254], and the Hochberg-adjusted 1-sided P-
value on stage 1 data. This testing procedure strongly controls the over-
all type I error rate at α level (see “Simulations run to assess the type I
error rate under several null hypothesis scenarios”). Multiplicity-adjusted
flexible repeated 95% 2-sided CIs [217] on the percentage of patients
will be calculated for otamixaban dose 1, otamixaban dose 2, and UFH
plus eptifibatide. Relative risk and its 95% 2-sided CIs will also be calcu-
lated. Point estimates based on the multiplicity-adjusted flexible re-
peated CIs will be used.” [181] See supplementary material of the paper
for details.
Example 4. Population-enrichment AD with SSR; criteria for claiming evi-
dence of benefit; methods for controlling familywise type I error; combin-
ation test weights
Mehta et al. [95] published a methodological paper detailing a family of
three hypotheses being tested; use of closure testing principle [254] to
control the overall type I error; how evidence is claimed; and analytical
derivations of the Simes adjusted p-values [255]. This includes the use of
a combination test approach using pre-defined weights based on the
accrued information fraction for the full population (cutaneous and non-
cutaneous patients) and subpopulation (cutaneous patients). Analytical
derivations were presented for the two cases assuming enrichment oc-
curs at interim analysis and no enrichment after interim analysis. Details
are reported in a supplementary file accessible via the journal website.
Example 5. Inferentially seamless (7-arm 2-stage) AD with dose selection;
use of traditional naïve estimates
“Unless otherwise stated, efficacy data are given as least squares means
with standard error (SE) or 95% confidence interval (CI).” [76]
Example 6. Inferentially seamless phase 2/3 (5-arm 2-stage) AD with dose
selection; dealing with overrunning participants
“Patients already assigned to an unselected regimen of propranolol by
(Continued)
the time that the conclusions of the interim analysis are available, will
continue the treatment according to the protocol but efficacy data for
these patients will not be included in the primary analysis of primary
endpoint.” [94] Extracted from the supplementary material.
Section 13. Results (Participant flow)
CONSORT 2010 item 13a: For each group, the numbers
of participants who were randomly assigned, received
intended treatment, and were analysed for the primary
outcome.
ACE item 13a (modification): For each group, the
numbers of participants who were randomly assigned,
received intended treatment, and were analysed for the
primary outcome and any other outcomes used to inform
pre-planned adaptations, if applicable.
Comments—Authors are referred to the CONSORT
2010 statement [3, 4] for detailed discussion. Here, we
only address additional requirements for ADs.
Explanation—The CONSORT 2010 statement [3, 4]
discusses why it is essential to describe participant flow
adequately from screening to analysis. This applies to
both interim and final analyses depending on the stage
of reporting. The number of participants for each group
with adaptation outcome data (that contributed to the
interim analyses) should also be reported if different
from the number of participants with primary outcome
data. Furthermore, authors should report the number
of randomised participants, for each group, that did
not contribute to each interim analysis because of
lack of mature outcome data at that interim look. For
example, overrunning participants that were still being
followed up when a terminal adaptation decision was
made (for example, dropping of treatment groups or early
trial termination). The presentation of participant flow
should align with the key hypotheses (for example,
subpopulation(s) and full study population) and treatment
comparisons depending on the stage of results being
reported.
See Box 18 for exemplars.
Box 18 Exemplars on reporting item 13 (participant flowcharts)
Example 1. Inferentially seamless phase 2/3 AD
Additional file 4 is an illustrative structure that could be used to show
the flow of participants when reporting the final results from a trial such
as ADVENT [252].
Example 2. Population enrichment AD
Additional files 5 and 6 illustrate participant flowcharts that could be
used for a population-enrichment adaptive trial such as TAPPAS [95],
which had key hypotheses relating to the cutaneous subpopulation and
full population (cutaneous and non-cutaneous) depending on whether
enrichment was done or not.
Example 3. Bayesian biomarker-targeted AD with RAR
Additional file 7 is an adapted flow diagram from BATTLE [256] showing
the number of participants that contributed to the analysis by
biomarker group (subpopulations) during fixed randomisation (burn-in
period) followed by RAR.
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Example 4. MAMS AD
Additional file 8 can be adapted for reporting a MAMS trial such as
TAILoR [257].
Section 14. Results (Recruitment)
CONSORT 2010 item 14a: Dates defining the periods of
recruitment and follow-up.
ACE item 14a (modification): Dates defining the
periods of recruitment and follow-up, for each group.
Comment—Authors should refer to the CONSORT
2010 statement [3, 4] for the discussion.
Explanation—Consumers of research findings should
be able to put trial results, study interventions, and
comparators into context. Some ADs, such as those that
evaluate multiple treatments allowing dropping of futile
ones, selection of promising treatments, or addition of
new treatments to an ongoing trial [19, 102, 258, 259],
incorporate pre-planned adaptations to drop or add new
treatment groups during the course of the trial. As a re-
sult, dates of recruitment and follow-up may differ
across treatment groups. In addition, the comparator
arm may also change with time and concurrent or non-
concurrent controls may be used. There are statistical
implications that include how analysis populations for
particular treatment comparisons are defined at different
stages. For each treatment group, authors should clearly
state the exact dates defining recruitment and follow-up
periods. It should be stated if all treatment groups were
recruited and followed-up during the same period.
See Box 19 for exemplars.
Box 19 Exemplars on reporting item 14a
Example 1. MAMS platform AD
Figure 2 illustrates the graphical reporting of recruitment and follow-up
periods for each treatment group including new arms that were added
during the STAMPEDE trial. Corresponding comparator groups (controls)
for treatment comparisons are indicated.
Example 2. Phase 2 Bayesian biomarker-targeted AD with RAR
“A total of 341 patients were enrolled in the BATTLE study between
November 30, 2006, and October 28, 2009, with equally random
assignments for the first 97 patients and adaptive randomization for the
remaining 158.” [256]
CONSORT 2010/ACE item 14b (clarification): Why the
trial ended or was stopped.
Comment—This item should be applied without
reference to the CONSORT 2010 statement [3, 4].
Explanation—Some clinical trials are stopped earlier
than planned for reasons that will have implications for
interpretation and generalisability of results. For example,
poor recruitment is a common challenge [261]. This may
limit the inference drawn or complicate interpretation of
results based on insufficient or truncated trial data. Thus,
the reporting of reasons for stopping a trial early including
circumstances leading to that decision could help readers
to interpret results with relevant caveats.
The CONSORT 2010 statement [3, 4], however, did
not distinguish early stopping of a trial due to a pre-
planned adaptation from an unplanned change. To ad-
dress this and for consistency, we have now reserved this
item for reporting of reasons why the trial or certain
treatment arm(s) were stopped outside the scope of pre-
planned adaptations, including those involved in deliber-
ations leading to this decision (for example, sponsor,
funder, or trial monitoring committee). We also intro-
duced item 14c to capture aspects of adaptation decisions
made in light of the accumulating data, such as stopping
the trial or treatment arm because the decision-making
criterion to do so has been met.
See Box 20 for exemplars.
Box 20 Exemplars on reporting item 14b
Example 1. 2-stage AD with options for futility and efficacy early stopping
and increase in sample size; unplanned trial termination
“The planned interim analysis of the study was done in November 2005
after 125 patients have been (sic) recruited.… According to the adaptive
design of the study, we therefore calculated another 163 patients per
treatment group to be required to answer the primary question. Upon
the slow accrual up to that timepoint, the study coordinators decided
to close the trial at the end of 2005. Further analysis was regarded to be
exploratory.” [194]
Example 2. Sequential-step AD; unplanned trial termination
“…the third interim analysis indicated unexpectedly low initial cure rates
in both arms; 84% in the multiple dose and 73% in the single-dose arm.
The stopping rule was not met …, but based on the observed poor effi-
cacy overall, and following discussions with the Data Safety and Moni-
toring Board (DSMB) and investigators, the sponsor terminated the trial.”
[262]
ACE item 14c (new): Specify what trial adaptation
decisions were made in light of the pre-planned decision-
making criteria and observed accrued data
Explanation—ADs depend on adherence to pre-
planned decision rules to inform adaptations. Thus, it is
vital for research consumers to be able to assess whether
the adaptation rules were adhered to as pre-specified in
the decision-making criteria given the observed accrued
data at the interim analyses. Failure to adhere to pre-
planned decision rules may undermine the integrity of
the results and validity of the design by affecting the op-
erating characteristics (see item 7b for details on binding
and non-binding decision rules).
Unforeseeable events can occur that may lead to
deviations from some pre-planned adaptation decisions
rules (for example, the overruling or ignoring of certain
rules). It is therefore essential to adequately describe
which pre-planned adaptations were enforced, which
were pre-planned but were not enforced or overruled
even though the interim analysis decision rules indicated
an adaptation should be made, and which unplanned
changes were made other than unplanned early stopping
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of the trial or treatment arm(s) covered by item 14b.
Pre-planned adaptations that were not implemented are
difficult to assess because the interim decisions made
versus the pre-planned intended decisions are often
poorly reported, and reasons are rarely given [115]. The
rationale for ignoring or overruling pre-planned adapta-
tion decisions, or making unplanned decisions that affect
the adaptations should be clearly stated and also who
recommended or made such decisions (for example, the
data monitoring committee or adaptation committee).
This enables assessment of potential bias in the adapta-
tion decision-making process, which is crucial for the
credibility of the trial.
Authors should indicate the point at which the
adaptation decisions were made (that is, stage of results)
and any additional design changes that were made as a
consequence of adaptation decisions (for example,
change in allocation ratio).
See Box 21 for exemplars.
Box 21 Exemplars on reporting item 14c elements
Example 1. Bayesian adaptive-enrichment AD with futility and superiority
early stopping; stage of results
“Enrolment in the trial was stopped at 31months, because the results of
an interim analysis met the pre-specified criterion for trial discontinu-
ation, which was a predictive probability of superiority of thrombectomy
of at least 95% for the first primary endpoint (the mean score for disabil-
ity on the utility-weighted modified Rankin scale at 90 days). This was
the first pre-specified interim analysis that permitted stopping for this
reason, and it was based on the enrolment of 200 patients. Because en-
richment thresholds had not been crossed, the analysis included the full
population of patients enrolled in the trial, regardless of infarct volume.”
[96]
Example 2. Dose-selection decisions for an inferentially seamless phase 2/3
AD
“The two doses of indacaterol selected against the two reference
efficacy criteria were 150 μg (as the lowest dose exceeding both criteria)
and 300 μg (as the next highest dose). The safety results, together with
the safety data from the other 1-year study, led the DMC to conclude
that there was no safety signal associated with indacaterol at any dose.
Thus, the two doses selected (at stage 1) to continue into stage 2 of the
study were indacaterol 150 and 300 μg.” [141]
Section 15. Results (Baseline data)
CONSORT 2010 item 15: A table showing baseline
demographic and clinical characteristics for each group.
ACE Item 15a «15 (clarification, renumbered): A table
showing baseline demographic and clinical
characteristics for each group.
Comments—We renumbered the item to
accommodate the new item 15b. This item should be
applied with reference to the CONSORT 2010 statement
[3, 4], with additional requirements for specific ADs.
Explanation—The presentation of treatment group
summaries of key characteristics and demographics of
randomised participants who contributed to results
influences interpretation and helps readers and medical
practitioners to make judgements about which patients
the results are applicable to. For some ADs, such as
population (or biomarker or patient) enrichment [83,
146], when the study population is considered
heterogeneous, a trial could be designed to evaluate if
study treatments are effective in specific pre-specified
subpopulations or a wider study population (full popula-
tion). A pre-planned adaptation strategy may involve
testing the effect of treatments in both pre-specified sub-
populations of interest and the wider population in
order to target patients likely to benefit the most. For
such ADs, it is essential to provide summaries of charac-
teristics of those who were randomised and who con-
tributed to the results being reported (both interim or
final), by treatment group for each subpopulation of
interest and the full population consistent with hy-
potheses tested. These summaries should be reported
without hypothesis testing of baseline differences in par-
ticipants’ characteristics because it is illogical in rando-
mised trials [263–266]. The CONSORT 2010 statement
[3, 4] presents an example of how to summarise baseline
characteristics.
In the presence of marked differences in the numbers
of randomised participants and those included in the
interim or final analyses, authors are encouraged to
report baseline summaries by treatment group for these
two populations. Readers will then be able to assess
representativeness of the interim or final analysis
population relative to those randomised and also the
target population.
See Box 22 for an exemplar.
Box 22 Exemplar on reporting item 15a
Example. Population-enrichment AD
See Additional file 9 for a dummy baseline table for the TAPPAS trial
[95].
ACE item 15b (new): Summary of data to enable the
assessment of similarity in the trial population between
interim stages.
Comment—This item is applicable for ADs conducted
in distinct stages for which the trial has progressed
beyond the first stage.
Explanation—Changes in trial conduct and other
factors may introduce heterogeneity in the characteristics
or standard management of patients before and after trial
adaptations. Consequently, results may be inconsistent or
heterogeneous between stages (interim parts) of the trial
[201]. For ADs, access to interim results or mere guesses
based on interim decisions taken may influence behaviour
of those directly involved in the conduct of the trial and
thus introduce operational bias [22]. Some trial
adaptations may introduce intended changes to inclusion
or exclusion criteria (for example, population enrichment
[88, 146]). Unintended changes to characteristics of
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patients over time may occur (population drift) [267].
A concern is whether this could lead to a trial with a
different study population that does not address the
primary research objectives [268]. This jeopardises
validity, interpretability, and credibility of trial results.
It may be difficult to determine whether differences
in characteristics between stages occurred naturally due to
chance, were an unintended consequence of pre-planned
trial adaptations, represent operational bias introduced by
knowledge or communication of interim results, or are for
other reasons [269]. However, details related to item 11c
may help readers make informed judgements on whether
any observed marked differences in characteristics be-
tween stages are potentially due to systematic bias or just
chance. Therefore, it is essential to provide key summary
data of participants included in the analysis (as discussed
in item 15a) for each interim stage of the trial and overall.
Authors are also encouraged to give summaries by stage
and treatment group. This will help readers assess similar-
ity in the trial population between stages and whether it is
consistent across treatment groups.
See Box 23 for an exemplar.
Box 23 Exemplar on reporting item 15b elements
Example. Overall baseline characteristics by stage; inferentially seamless
phase 2/3 AD. See Table 5
Section 16. Results (Numbers analysed)
CONSORT 2010/ACE item 16 (clarification): For each
group, number of participants (denominator) included in
each analysis and whether the analysis was by original
assigned groups.
Comments—The item should be used in reference to
the CONSORT 2010 statement [3, 4] for original details
and examples. Here, we give additional clarification for
some specific requirements of certain ADs such as
population enrichment [83, 146].
Explanation—We clarify that the number of par-
ticipants by treatment group should be reported for
each analysis at both the interim analyses and final
analysis whenever a comparative assessment is
performed (for example, for efficacy, effectiveness, or
safety). Most importantly, the presentation should
reflect the key hypotheses considered to address the
research questions. For example, population (or
patient or biomarker) enrichment ADs can be
reported by treatment group for each pre-specified
subpopulation and full population depending on key
hypotheses tested.
Section 17. Results (Outcomes and estimation)
CONSORT 2010/ACE item 17a (clarification): For each
primary and secondary outcome, results for each group,
and the estimated effect size and its precision (such as
95% confidence interval).
Comments—We expanded the explanatory text to
address some specific requirements of certain ADs such
as population enrichment [146]. Therefore, the item
should be used in reference to the CONSORT 2010 [3]
for original details and examples.
Explanation—In randomised trials, we analyse par-
ticipant outcome data collected after study treatments
are administered to address research questions about
beneficial and/or harmful effects of these treatments. In
principle, reported results should be in line with the
pre-specified estimand(s) and compatible with the re-
search questions or objectives [206, 207]. The CON-
SORT 2010 statement [3, 4] addresses what authors
should report depending on the outcome measures.
These include group summary measures of effect, for
both interim and final analyses, including the number
of participants contributing to the analysis, appropri-
ate measures of the treatment effects (for example,
between group effects for a parallel group randomised
trial) and associated uncertainty (such as credible or
confidence intervals). Importantly, the presentation is
influenced by how the key hypotheses are configured
to address the research questions. For some ADs,
such as population (or biomarker or patient) enrich-
ment, key hypotheses often relate to whether the
study treatments are effective in the whole target
population of interest or in specific subpopulations of
the target population classified by certain characteris-
tics. In such ADs, reporting of results as detailed in
the CONSORT 2010 should mirror hypotheses of
interest. That is, we expect the outcome results to be
presented for the subpopulations and full target popu-
lation considered by treatment group. This is to help
Table 5 Characteristics of randomised participants (N = 1202) in
stage 1 and 2
Characteristic Stage 1
(n = 230)
Stage 2
(n = 972)
Age (years), mean (SD) 53.4 (10.3) 54.3 (9.7)
Gender (female), n (%) 139 (60.4) 504 (51.9)
Race (white), n (%) 103 (44.8) 509 (52.4)
BMI (kg/m2), mean (SD) 31.9 (4.5) 31.1 (4.3)
Body weight (kg), mean (SD) 87.3 (18.0) 86.2 (17.1)
Duration of diabetes (years), mean (SD) 7.5 (5.5) 7.0 (5.1)
Seated systolic BP (mm Hg), mean (SD) 128.0 (14.4) 127.7 (13.1)
Seated diastolic BP (mm Hg), mean (SD) 77.9 (7.9) 77.6 (8.6)
Seated heart rate (bpm), mean (SD) 74.5 (9.6) 75.2 (10.0)
Adapted from Geiger et al. [166]; BMI Body Mass Index, SD standard deviation,
BP blood pressure, bpm beats per minute, mm Hg millimetres of mercury. Data
presented were from an ongoing trial so are incomplete and only used
for illustration
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readers interpret results on whether the study treat-
ments are beneficial to the target population as a
whole or only to specific pre-specified subpopulations.
ACE item 17c (new): Report interim results used to
inform interim decision-making.
Explanation—Adherence to pre-planned adaptations
and decision rules including timing and frequency is es-
sential in AD randomised trials. This can only be
assessed when the pre-planned adaptations (item 3b),
adaptive decision rules (item 7b), and results that are
used to guide the trial adaptations are transparently and
adequately reported.
Marked differences in treatment effects between
stages may arise (for example, discussed in item 15b)
making overall interpretation of their results difficult
[88, 110, 267, 269–272]. The presence of
heterogeneity questions the rationale for combining
results from independent stages to produce overall
evidence, as is also the case for combining individual
studies in a meta-analysis [88, 273]. Although this
problem is not unique to AD randomised trials, con-
sequences of trial adaptation may worsen the problem
[269]. Authors should at least report the relevant in-
terim or stage results that were used to make each
adaptation, consistent with items 3b and 7b; for ex-
ample, interim treatment effects with uncertainty, in-
terim conditional power or variability used for SSR,
and trend in the probabilities of allocating partici-
pants to a particular treatment group as the trial pro-
gresses. Authors should report interim results of
treatment groups or subpopulations that have been
dropped due to lack of benefit or poor safety. This
reduces the reporting bias caused by selective disclos-
ure of treatments only showing beneficial and/or less
harmful effects.
See Box 24 for exemplars.
Box 24 Exemplars on reporting item 17 elements
Example 1. Bayesian RAR; change in randomisation probabilities across
arms throughout the trial; randomisation updates were made after every
patient
Giles et al. [67] present a table of changes in allocation probabilities
used to create Fig. 3 by treatment group including allocated treatment
and primary outcome response for each participant.
Example 2. Inferentially seamless phase 2/3 AD; stage 1 treatment selection
results
Barnes et al. [141] clearly presented the results that led to the interim
selection of the two indacaterol drug doses to progress to stage 2 of
the study; 150 μg (the lowest dose that exceeded both pre-specified
treatment selection criteria) and 300 μg (the next highest dose that met
the same criteria). The interim difference in treatment effect compared
to placebo with uncertainty per group for the two adaptation outcomes
are displayed in Figs. 1 and 2 of the paper.
Example 3. 2-stage GSD; stage 1 dose selection results
“At the interim analysis planned after at least 1969 patients had been
randomized and reached day 7 follow-up in each group [181], the ota-
mixaban dose for stage 2 of the trial was selected as described in eFi-
gure 1 in the Supplement. At that time, the rates of the primary efficacy
outcome in the higher-dose otamixaban group was xx (4.7%) (the one
selected to go forward) and was xx (5.6%) in the UFH-pluseptifibatide
group (adjusted RR, 0.848; 95% CI, 0.662–1.087) but the lower-dose
group fulfilled the pre-specified criteria for futility with a RR of more
than 1 (primary efficacy outcome, xx (6.3%); RR, 1.130; 95% CI, 0.906–
1.408) and was discontinued.” [144] xx are the corresponding number of
participants with primary response that should have been stated.
Example 4. Adapted from Khalil et al [143]; sequential-step AD. See Table 6
Fig. 3 Redrawn from Pallmann et al. [22] Reused in accordance with the terms of Creative Commons Attribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made
Dimairo et al. Trials          (2020) 21:528 Page 23 of 34
Section 20. Discussion (Limitations)
CONSORT 2010/ACE item 20 (clarification): Trial
limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses.
Comments—No change in wording is made to this item
so it should be applied with reference to the CONSORT
2010 statement [3, 4] for original details and examples.
Here, we only address additional considerations for ADs.
Explanation—We expect authors to discuss the
arguments for and against the implemented study
design and its findings. Several journals have guidelines
for structuring the discussion to prompt authors to
discuss key limitations with possible explanations. The
CONSORT 2010 statement [3, 4] addresses general
aspects relating to potential sources of bias, imprecision,
multiplicity of analyses and implications of unplanned
changes to methods or design. For AD randomised trials,
further discussion should include the implications of:
▪ Any deviations from the pre-planned adaptations (for
example, decision rules that were not enforced or over-
ruled and changes in timing or frequency of interim
analyses);
▪ Interim analyses (for example, updating
randomisation with inadequate burn-in period);
▪ Protocol amendments on the trial adaptations and
results;
▪ Potential sources of bias introduced by interim
analyses or decision-making;
▪ Potential bias and imprecision of the treatment
effects if naïve estimation methods were used;
▪ Potential heterogeneity in patient characteristics and
treatment effects between stages;
▪ Whether outcome data (for example, efficacy and
safety data) were sufficient to robustly inform trial
adaptations at interim analyses and;
▪ Using adaptation outcome(s) different from the
primary outcome(s).
Additionally, it is encouraged to discuss the observed
efficiencies of pre-planned adaptations in addressing the
research questions and lessons learned about using the
AD, both negative and positive. This is optional as it
does not directly influence the interpretation of the re-
sults but enhances much-needed knowledge transfer of
innovative trial designs. Therefore, authors have been
encouraged to consider separate methodology publica-
tions in addition to trial results [54, 181].
See Box 25 for exemplars.
Box 25 Exemplars on reporting item 20
Example 1. Use of surrogate outcome to inform adaptation
“We chose change in the SOFA scores as a surrogate outcome based on
strong correlations between this measure and 28-day mortality (33).
Whether change in the SOFA scores and the timing of reassessment (48
h in this case) represents the “right” surrogate endpoint for nonpivotal
sepsis trials remains unclear and is an area for future consideration, al-
though the use of change in the SOFA score as a surrogate outcome is
supported by a recent meta-analysis (34).” [142]
Example 2. Duration of assessments to inform dose selection
“The use of the adaptive seamless design is not without potential risk.
The initial dose-finding period needs to be long enough for a thorough
evaluation of effects. Two weeks was considered a fully adequate period
in which to attain pharmacodynamic steady state….” [141]
Example 3. Early stopping outside the scope of the pre-planned adaptation
and possible explanation
“The aim was to determine the minimum efficacious dose and safety of
treatments in HIV-uninfected patients. However, the study had to be
prematurely terminated due to unacceptably low efficacy in both the
single and multiple dose treatment arms, with a cure rate of only 85%
in the multiple-dose arm. Adverse effects of treatment in this study were
in line with the current drug label. The overall low efficacy was unex-
pected, as total doses of 10 mg/kg and above resulted in DC rates of at
least 90% in a trial in Kenya (13). The trial was not powered for data ana-
lysis by geographical location (centre) and the results may have been
due to chance, but both the 10 mg/kg single dose and 21mg/kg mul-
tiple dose regimens appeared to work very well in the small number of
patients treated in Arba Minch Hospital (southern Ethiopia). We have lit-
tle explanation for the overall poor response seen in this study or for
the observed geographical variations. Previously, similar geographical
Table 6 Interim results
Parasite clearance at day 30 (initial
cure)
Treatment group Parasite clearance rate, n/N
(%)
Differences in parasite clearance rates (95%
CI)
P-
value
Interim analysis 1 Single dose, 7.5 mg/kg 10/20 (50.0%) Reference
Multiple dose, 7x3mg/
kg
16/18 (88.9%) 38.9% (12.6 to 65.2) 0.015a
Interim analysis 2b Single dose, 10 mg/kg 16/20 (80.0%) Reference
Multiple dose, 7x3mg/
kg
19/25 (76.0%) −4.0% (−28.2 to 20.2) 0.748c
Interim analysis 3d Single dose, 10 mg/kg 29/40 (72.5%) Reference
Multiple dose, 7x3mg/
kg
37/44 (84.1%) 11.6% (−6.0 to 29.1) 0.196e
N, total number of patients per group (denominator); n, patients with recorded parasitic clearance per groups (events); CI, confidence interval
ap-value from Fisher’s exact test, adaptation rule met to escalate dose so dosage increased to 10mg/kg and continue recruitment
badaptation rule to escalate dose not met so recruitment was continued with the same dosage (10 mg/kg in single-dose arm
c, e p-values from a Chi-square test
d includes patients in interim analysis 2; patients in interim analysis 1 did not contribute to any subsequent interim analysis
e adaptation rule to escalate dose not met but concerns arose regarding low cure in each arm and recruitment was terminated
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(Continued)
variation in treatment response in these three sites was seen for daily
doses of 11 mg/kg body weight paromomycin base over 21 days (7), a
regimen which had also proven efficacious in India (18). Methodological
bias is unlikely in this randomized trial, but differences in base line pa-
tient characteristics between the three trial sites could have possibly in-
troduced bias, leading to variation in treatment response….” [143]
Example 4. Limitations of biomarkers and RAR
“Our study has some important limitations. First, and probably most
important, our biomarker groups were less predictive than were
individual biomarkers, which diluted the impact of strong predictors in
determining treatment probabilities. For example, EGFR mutations were
far more predictive than was the overall EGFR marker group. The
unfortunate decision to group the EGFR markers also impacted the
other marker groups and their interactions with other treatments,
resulting in a suboptimal overall disease control rate as described.
Second, several of the pre-specified markers (for example, RXR) had little,
if any, predictive value in optimizing treatment selections. This limitation
will be addressed in future studies by not grouping or prespecifying bio-
markers prior to initiating these biopsy-mandated trials. In addition,
adaptive randomization, which assigns more patients to the more effect-
ive treatments within each biomarker group, only works well with a
large differential efficacy among the treatments (as evident in the KRAS/
BRAF group), but its role is limited without such a difference (for ex-
ample, in the other marker groups). Allowing prior use of erlotinib was
another limitation and biased treatment assignments; in fact, the per-
centage of patients previously treated with erlotinib steadily increased
during trial enrollment. Overall, 45% of our patients were excluded from
the 2 erlotinib-containing arms because of prior EGFR TKI treatment. As
erlotinib is a standard of care therapy in NSCLC second-line, mainten-
ance, and front-line settings, the number of patients receiving this tar-
geted agent will likely continue to increase.” [256]
Section 21. Discussion (Generalisability)
CONSORT 2010/ACE item 21 (clarification):
Generalisability (external validity, applicability) of the
trial findings.
Comments—We have not changed the wording of this
item so it should be considered in conjunction with the
CONSORT 2010 statement [3, 4]. However, there are
additional considerations that may influence the
generalisability of results from AD randomised trials.
Explanation—Regardless of the trial design, authors
should discuss how the results are generalisable to other
settings or situations (external validity) and how the
design and conduct of the trial minimised or mitigated
potential sources of bias (internal validity) [3]. For ADs,
there are many factors that may undermine both internal
(see item 20 clarifications) and external validity. Trial
adaptations are planned with a clear rationale to achieve
research goals or objectives. Thus, the applicability of
the results may be intentionally relevant to the target
population enrolled or pre-specified subpopulation(s)
with certain characteristics (subsets of the target
population). Specifically, the implemented adaptations
and other factors may cause unintended population
drift or inconsistencies in the conduct of the trial.
Authors should discuss the population to whom the
results are applicable including any threats to internal
and external validity which are trial dependent based
on the implemented adaptations.
See Box 26 for exemplars.
Box 26 Exemplar on reporting item 21 elements
Example 1. Bayesian population-enrichment AD with RAR; to whom the re-
sults are applicable (full population)
“The DAWN trial showed that, among patients with stroke due to
occlusion of the intracranial internal carotid artery or proximal middle
cerebral artery who had last been known to be well 6 to 24 h earlier
and who had a mismatch between the severity of the clinical deficit
and the infarct volume, outcomes for disability and functional
independence at 90 days were better with thrombectomy plus standard
medical care than with standard medical care alone.” [96]
Example 2. Phase 2 Bayesian biomarker-targeted AD with RAR; to whom
the results are applicable (biomarker specific)
“Sorafenib was active against tumors with mutated or wild-type KRAS,
but had a worse disease control rate (compared with other study
agents) in patients with EGFR mutations. As expected (5–7, 15–17), erlo-
tinib was beneficial in patients with mutated-EGFR tumors. Erlotinib plus
bexarotene improved disease control in patients with a higher expres-
sion of Cyclin D1, suggesting a potential role for bexarotene in lung
cancer treatment (11); similar to sorafenib, the combination also im-
proved disease control in the KRAS-mutant patient population. Future
randomized, controlled studies are needed to further confirm the pre-
dictive value of these biomarkers.” [256] Liu and Lee [81] published de-
tails of the design and conduct of this trial.
Section 24. Other information (Statistical analysis plan
and other relevant trial documents)
ACE item 24b (new): Where the full statistical analysis
plan and other relevant trial documents can be accessed.
Explanation—Pre-specifying details of statistical
methods and their execution including documentation
of amendments and when they occurred is good scientific
practice that enhances trial credibility and reproducibility
of methods, results and inference. The SAP is the
principal technical document that details the statistical
methods for the design of the study; analysis of the
outcomes; aspects that influence the analysis approaches;
and presentation of results consistent with the research
questions/objectives and estimands [206, 207] in line with
the trial protocol (now item 24a). General guidance on
statistical principles for clinical trials to consider with the
aim to standardise research practice exists [274–276]. AD
trials tend to bring additional statistical complexities and
considerations during the design and analyses depending
on the trial adaptations considered. Access to the full SAP
with amendments (if applicable) addressing interim and
final analyses is essential. This can be achieved through
the use of several platforms such as online supplementary
material, online repositories, or referencing published
material. This enables readers to access additional
information relating to the statistical methods that may
not be feasible to include in the main report.
Critical details of the trial adaptations (for example,
the decision-making criteria or adaptation algorithm and
rules) may be intentionally withheld from publicly
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accessible documents (for example, protocol) while the
trial is ongoing [41, 203]. These details may be docu-
mented in a formal document with restricted access and
disclosed only when the trial is completed in order to
minimise operational bias (item 11c). For this situation,
authors should provide access to such details withheld
with any amendments made for transparency and an
audit trail of pre-planned AD aspects.
For some AD randomised trials, methods to derive
statistical properties analytically may not be available.
Thus, it becomes necessary to perform simulations under
a wide range of plausible scenarios to investigate the
operating characteristics of the design (item 7a), impact
on estimation bias (item 12b), and appropriateness
and consequences of decision-making criteria and
rules [154, 277]. In such cases, we encourage authors
to reference accessible material used for this purpose
(for example, simulation protocol and report, or pub-
lished related material). Furthermore, it is good scien-
tific practice to reference software, programs or code
used for this task to facilitate reproducible research.
The operating characteristics of ADs heavily depend
on following the pre-planned adaptations and adaptive
decision-making criteria and rules. ADs often come with
additional responsibilities for the traditional monitoring
committees or require a specialised monitoring commit-
tee to provide independent oversight of the trial adapta-
tions (for example, adaptive decision-making or
adaptation committee). Thus, it is essential to be trans-
parent about the adaptation decision-making process,
roles and responsibilities of the delegated DMC(s),
recommendations made by the committee and whether
recommendations were adhered to. Authors are encour-
aged to provide supporting evidence (for example, DMC
charter).
See Box 27 for exemplars.
Box 27 Exemplars on reporting item 24b
Example 1. Interim and final SAPs; IDMC roles and responsibilities;
supplementary material
Léauté-Labrèze et al. [94] provide several versions of the SAP for a 2-
stage inferentially seamless phase 2/3 AD as supplementary material.
The remit and responsibilities of the IDMC including involvement in the
adaptation decision-making process are detailed. The last version (3.5) of
the SAP with amendments and details of interim and final analyses is
found on pages 759 to 830 of the protocol supplementary material.
Simulation results are summarised on pages 831 to 836.
Example 2. Simulation report; supplementary material
Steg et al. [181] provide a simulation report evaluating the operating
characteristics of a 3-arm 2-stage group sequential AD with dose selec-
tion under a number of scenarios in an appendix. The authors also ex-
plored the bias in methods used to estimate the treatment effects and
confidence intervals and used the simulation results to inform their
choice of methods.
Example 3. Set-up of simulation studies and simulation results; published
methodology work
Gu et al. [208] describe how simulation studies were performed and
presented simulation results for evaluating operating characteristics of a
2-stage Bayesian biomarker-based AD.
(Continued)
Example 4. Simulation report; published methodology work
Skrivanek et al. [154] published extensive simulation work quantifying
operating characteristics of a Bayesian inferentially seamless phase 2/3
AD with RAR.
Example 5. Simulation report; published methodology work
Heritier et al. [63] published extensive simulation work for an
inferentially seamless phase 2/3 design using frequentist methods.
Conclusions
There is a multidisciplinary desire to improve efficiency
in the conduct of randomised trials. ADs allow pre-
planned adaptations that offer opportunities to address
research questions in randomised trials more efficiently
compared to fixed designs. However, ADs can make the
design, conduct and analysis of trials more complex.
Potential biases can be introduced during the trial in
several ways. Consequently, there are additional de-
mands for transparency and reporting to enhance the
credibility and interpretability of results from adaptive
trials.
This CONSORT extension provides minimum essential
reporting requirements that are applicable to pre-planned
adaptations in AD randomised trials, designed and ana-
lysed using frequentist or Bayesian statistical methods. We
have also given many exemplars of different types of ADs
to help authors when using this extension. Our consensus
process involved stakeholders from the public and private
sectors [13, 128]. We hope this extension will facilitate
better reporting of randomised ADs and indirectly im-
prove their design and conduct, as well as much-needed
knowledge transfer.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04334-x.
Additional file 1: Appendix A. Main ACE checklist available to
download.
Additional file 2: Appendix B. Additional examples of Box 13.
Additional file 3: Appendix C. Example 2 of Box 14 (Bayesian RAR).
Additional file 4: Appendix D. Example of a CONSORT flowchart for
reporting 2-stage adaptive design (such as inferential seamless) that use
combination test methods.
Additional file 5: Appendix E. Example of a CONSORT flowchart for
reporting a population enrichment adaptive design (assuming
enrichment was done at an interim analysis).
Additional file 6: Appendix F. Example of a CONSORT flowchart for
reporting a population enrichment adaptive design (assuming
enrichment was not done at an interim analysis).
Additional file 7: Appendix G. Example of a CONSORT flowchart for
reporting a response-adaptive randomisation adaptive design with
frequent randomisation updates.
Additional file 8: Appendix H. Example of a CONSORT flowchart for
reporting a MAMS adaptive design.
Additional file 9: Appendix I. Box 22 - Dummy baseline table for the
TAPPS trial.
Dimairo et al. Trials          (2020) 21:528 Page 26 of 34
Abbreviations
ACE: Adaptive designs CONSORT Extension; AD: Adaptive design;
CONSORT: Consolidated Standards Of Reporting Trials; E&E: Explanation and
elaboration; EQUATOR: Enhancing the QUAlity and Transparency Of health
Research; (I)DMC: (independent) data monitoring committee; GSD: Group
sequential design; MAMS: Multi-arm multi-stage design; MeSH: Medical
Subject Heading; RAR: Response-adaptive randomisation; SAP: Statistical
analysis plan; SSR: Sample size re-estimation/re-assessment/re-calculation
Acknowledgements
ACE Consensus Group: We are very grateful to the consensus meeting
participants who provided recommendations on reporting items to retain in
this guidance and for comments on the structure of this E&E document. All
listed members approved the final ACE checklist and offered opportunity to
review this E&E document. Sally Hopewell joined the group during the write
up stage to oversee the process on behalf of the CONSORT Group following
the sad passing of Doug G Altman.
Munyaradzi Dimairo1; Toshimitsu Hamasaki2; Susan Todd3; Christopher J
Weir4; Adrian P Mander5; James Wason5 6; Franz Koenig7; Steven A Julious8;
Daniel Hind1; Jon Nicholl1; Douglas G Altman9; William J Meurer10;
Christopher Cates11; Matthew Sydes12; Yannis Jemiai13; Deborah Ashby14
(chair); Christina Yap15; Frank Waldron-Lynch16; James Roger17; Joan Marsh18;
Olivier Collignon19; David J Lawrence20; Catey Bunce21; Tom Parke22; Gus Gaz-
zard23; Elizabeth Coates1; Marc K Walton25; Sally Hopewell9.
1 School of Health and Related Research, University of Sheffield, Sheffield, UK.
2 National Cerebral and Cardiovascular Center, Osaka, Japan.
3 Department of Mathematics and Statistics, University of Reading, Reading,
UK.
4 Edinburgh Clinical Trials Unit, Centre for Population Health Sciences, Usher
Institute of Population Health Sciences and Informatics, The University of
Edinburgh, Edinburgh, UK.
5 MRC Biostatistics Unit, University of Cambridge, School of Clinical Medicine,
Cambridge Institute of Public Health, Cambridge, UK.
6 Institute of Health and Society, Newcastle University, UK.
7 Medical University of Vienna, Center for Medical Statistics, Informatics, and
Intelligent Systems, Vienna, Austria.
8 Medical Statistics Group, School of Health and Related Research, University
of Sheffield, Sheffield, UK.
9 Centre for Statistics in Medicine, Nuffield Department of Orthopaedics,
Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford,
UK.
10 Departments of Emergency Medicine and Neurology, University of
Michigan, Ann Arbor, MI, USA.
11 Cochrane Airways, PHRI, SGUL, London, UK.
12 MRC Clinical Trials Unit, UCL, Institute of Clinical Trials and Methodology,
London, UK.
13 Cytel, Cambridge, USA.
14 School of Public Health, Imperial College London, UK.
15 Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic
Sciences, College of Medical and Dental Sciences, University of Birmingham,
Birmingham, UK.
16 Novartis Institutes for Biomedical Research, Basel, Switzerland.
17 Institutional address not applicable.
18 The Lancet Psychiatry, London, UK.
19 Luxembourg Institute of Health, Strassen, Luxembourg.
20 Novartis Campus, Basel, Switzerland.
21 School of Population Health and Environmental Sciences, Faculty of Life
Sciences and Medicine, King’s College London, London, UK.
21 Berry Consultants, Merchant House, Abingdon, UK.
23 NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL
Institute of Ophthalmology, London, UK.
25 Janssen Research and Development, Ashton, USA.
ACE Steering Committee: Munyaradzi Dimairo, Elizabeth Coates, Philip
Pallmann, Susan Todd, Steven A Julious, Thomas Jaki, James Wason, Adrian P
Mander, Christopher J Weir, Franz Koenig, Marc K Walton, Katie Biggs, Jon P
Nicholl, Toshimitsu Hamasaki, Michael A Proschan, John A Scott, Yuki Ando,
Daniel Hind, Douglas G Altman.
External Expert Panel: We would like to thank William Meurer (University of
Michigan, Departments of Emergency Medicine and Neurology, Ann Arbor,
MI, USA); Yannis Jemiai (Cytel, Cambridge, USA); Stephane Heritier (Monash
University, Department of Epidemiology and Preventive Medicine, School of
Public Health and Preventive Medicine, Australia); and Christina Yap (Cancer
Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences,
University of Birmingham, Birmingham, UK) for their invaluable contributions
in reviewing the checklist and working definitions of technical terms.
Administrative support: We thank Sarah Gonzalez for coordination and
administrative support throughout the project; Sheffield Clinical Trials
Research Unit for their support, particularly Mike Bradburn and Cindy Cooper;
and Benjamin Allin and Anja Hollowell for the Delphi surveys technical and
administrative support.
Delphi survey participants: We are grateful for the input of several key
stakeholders during the Delphi surveys and many who gave informal advice.
Other support: Trish Groves contributed to the consensus workshop,
reviewed and approved the finalised ACE checklist. Lingyun Liu provided
dummy baseline information for the TAPPAS trial.
Authors’ contributions
The idea originated from MD’s NIHR Doctoral Research Fellowship (DRF-
2012-05-182) under the supervision of SAJ, ST, and JPN. The idea was
presented, discussed, and contextualised at the 2016 annual workshop of
the MRC Network of HTMR Adaptive Designs Working Group (ADWG), which
was attended by six members of the Steering Committee (MD, TJ, PP, JW,
APM, and CJW). MD, JW, TJ, APM, ST, SAJ, FK, CJW, DH, and JPN
conceptualised the study design and applied for funding. All authors
contributed to the conduct of the study and interpretation of the results.
MD, ST, PP, CJW, JW, TJ and SAJ led the write-up of the manuscript. All au-
thors except DGA contributed to the writeup of the manuscript, reviewed,
and approved this final version. DGA oversaw the development process on
behalf of the CONSORT Group and also contributed to the initial draft manu-
script until his passing after the approval of the final checklists. The Steering
Committee is deeply saddened by the passing of DGA who did not have
the opportunity to approve the final manuscript. We dedicate this work to
him in memory of his immense contribution to the ACE project, medical sta-
tistics, good scientific research practice and reporting, and humanity.
Members of the ACE Consensus Group contributed to the consensus
workshop, approved the final ACE checklist, and were offered the
opportunity to review the final manuscript.
Funding
This paper summarises independent research jointly funded by the National
Institute for Health Research (NIHR) Clinical Trials Unit Support Funding
scheme and the Medical Research Council (MRC) Network of Hubs for Trials
Methodology Research (HTMR) (MR/ L004933/− 2/N90).
The funders had no role in the design of the study and collection, analysis,
and interpretation of data and in writing or approving the manuscript.
MD, JW, TJ, APM, ST, SAJ, FK, CJW, DH, and JN were co-applicants who
sourced funding from the NIHR CTU Support Funding scheme. MD, JW and
TJ sourced additional funding from the MRC HTMR.
TJ’s contribution was in part funded by his Senior Research Fellowship
(NIHR-SRF-2015-08-001) funded by NIHR. NHS Lothian via the Edinburgh
Clinical Trials Unit supported CW in this work. The University of Sheffield via
the Sheffield Clinical Trials Unit and the NIHR CTU Support Funding scheme
supported MD’s contribution. An MRC HTMR grant (MR/L004933/1-R/N/P/B1)
partly funded PP’s contribution.
The views expressed are those of the authors and not necessarily those of
the National Health Service (NHS), the NIHR, the MRC, the Department of
Health and Social Care, US Food and Drug Administration, or Pharmaceutical
and Medical Devices Agency, Japan.
Availability of data and materials
Not applicable. We have published the development process of this
guideline including anonymised participant data from Delphi surveys which
is publicly accessible [13].
Ethics approval and consent to participate
The project ethics approval was granted by the Research Ethics Committee
of the School of Health and Related Research (ScHARR) at the University of
Sheffield (ref: 012041). All Delphi participants during the development of the
ACE guideline provided consent online during survey registration.
Consent for publication
Not applicable.
Dimairo et al. Trials          (2020) 21:528 Page 27 of 34
Competing interests
MKW is an employee of Janssen Research and Development, Inc. All other
authors declare no competing interests.
Author details
1School of Health and Related Research, University of Sheffield, Sheffield S1
4DA, UK. 2Centre for Trials Research, Cardiff University, Cardiff, UK. 3MRC
Biostatistics Unit, University of Cambridge, Cambridge, UK. 4Institute of
Health and Society, Newcastle University, Newcastle, UK. 5Department of
Mathematics and Statistics, University of Reading, Reading, UK. 6Department
of Mathematics and Statistics, Lancaster University, Lancaster, UK. 7Edinburgh
Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
8Centre for Medical Statistics, Informatics, and Intelligent Systems, Medical
University of Vienna, Vienna, Austria. 9Janssen Pharmaceuticals, Titusville, New
Jersey, USA. 10National Cerebral and Cardiovascular Center, Osaka, Japan.
11National Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, USA. 12Division of Biostatistics in the Center for Biologics
Evaluation and Research, Food and Drug Administration, Rockville, USA.
13Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. 14Centre for
Statistics in Medicine, University of Oxford, Oxford, UK.
References
1. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P.
Avoidable waste of research related to inadequate methods in clinical trials.
BMJ. 2015;350:h809. https://doi.org/10.1136/bmj.h809.
2. Chen YL, Yang KH. Avoidable waste in the production and reporting of
evidence. Lancet. 2009;374:786. https://doi.org/10.1016/S0140-
6736(09)61591-9.
3. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group randomised
trials. BMJ. 2010;340:c869. https://doi.org/10.1136/bmj.c869.
4. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010
statement: updated guidelines for reporting parallel group randomized
trials. Ann Intern Med. 2010;152:726–32. https://doi.org/10.7326/0003-4819-
152-11-201006010-00232.
5. CONSORT Group. Extensions of the CONSORT statement http://www.
consort-statement.org/extensions.
6. Ivers NM, Taljaard M, Dixon S, et al. Impact of CONSORT extension for
cluster randomised trials on quality of reporting and study methodology:
review of random sample of 300 trials, 2000-8. BMJ. 2011;343:d5886. https://
doi.org/10.1136/bmj.d5886.
7. Moher D, Jones A, Lepage L, CONSORT Group (Consolidated Standards for
Reporting of Trials). Use of the CONSORT statement and quality of reports
of randomized trials: a comparative before-and-after evaluation. JAMA. 2001;
285:1992–5. https://doi.org/10.1001/jama.285.15.1992.
8. Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the
quality of reports of randomised controlled trials? A systematic review. Med J
Aust. 2006;185:263–7. https://doi.org/10.5694/j.1326-5377.2006.tb00557.x.
9. Blanco D, Biggane AM, Cobo E, MiRoR network. Are CONSORT checklists
submitted by authors adequately reflecting what information is actually
reported in published papers? Trials. 2018;19:80. https://doi.org/10.1186/
s13063-018-2475-0.
10. Jin Y, Sanger N, Shams I, et al. Does the medical literature remain
inadequately described despite having reporting guidelines for 21 years? - a
systematic review of reviews: an update. J Multidiscip Healthc. 2018;11:495–
510. https://doi.org/10.2147/JMDH.S155103.
11. Janackovic K, Puljak L. Reporting quality of randomized controlled trial
abstracts in the seven highest-ranking anesthesiology journals. Trials. 2018;
19:591. https://doi.org/10.1186/s13063-018-2976-x.
12. Goldacre B, Drysdale H, Dale A, et al. COMPare: a prospective cohort study
correcting and monitoring 58 misreported trials in real time. Trials. 2019;20:
118. https://doi.org/10.1186/s13063-019-3173-2.
13. Dimairo M, Coates E, Pallmann P, et al. Development process of a
consensus-driven CONSORT extension for randomised trials using an
adaptive design. BMC Med. 2018;16:210. https://doi.org/10.1186/s12916-018-
1196-2.
14. FDA. Adaptive designs for medical device clinical studies: draft guidance for
industry and food and drug administration staff. 2015. https://www.fda.gov/
ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/
ucm446729.pdf.
15. Chow S-C, Chang M. Adaptive design methods in clinical trials - a review.
Orphanet J Rare Dis. 2008;3:11. https://doi.org/10.1186/1750-1172-3-11.
16. Dragalin V. Adaptive designs: terminology and classification. Drug Inf J.
2006;40:425–35. https://doi.org/10.1177/216847900604000408.
17. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J, PhRMA
Working Group. Adaptive designs in clinical drug development--an
executive summary of the PhRMA Working Group. J Biopharm Stat. 2006;16:
275–83, discussion 285–91, 293–8, 311–2. https://doi.org/10.1080/
10543400600614742.
18. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a
review of barriers and opportunities. Trials. 2012;13:145. https://doi.org/10.
1186/1745-6215-13-145.
19. Lewis RJ. The pragmatic clinical trial in a learning health care system. Clin
Trials. 2016;13:484–92. https://doi.org/10.1177/1740774516655097.
20. Curtin F, Heritier S. The role of adaptive trial designs in drug development.
Expert Rev Clin Pharmacol. 2017;10:727–36. https://doi.org/10.1080/
17512433.2017.1321985.
21. Park JJ, Thorlund K, Mills EJ. Critical concepts in adaptive clinical trials. Clin
Epidemiol. 2018;10:343–51. https://doi.org/10.2147/CLEP.S156708.
22. Pallmann P, Bedding AW, Choodari-Oskooei B, et al. Adaptive designs in
clinical trials: why use them, and how to run and report them. BMC Med.
2018;16:29. https://doi.org/10.1186/s12916-018-1017-7.
23. Jaki T, Wason JMS. Multi-arm multi-stage trials can improve the efficiency of
finding effective treatments for stroke: a case study. BMC Cardiovasc Disord.
2018;18:215. https://doi.org/10.1186/s12872-018-0956-4.
24. Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments within a
single protocol over 10 years at MRC clinical trials unit at UCL: multi-arm,
multi-stage platform, umbrella and basket protocols. In: Clinical trials. UK:
SAGE Publications Sage; 2017. p. 451–61. https://doi.org/10.1177/
1740774517725697.
25. Porcher R, Lecocq B, Vray M, participants of Round Table N° 2 de Giens
XXVI. Adaptive methods: when and how should they be used in clinical
trials? Therapie. 2011;66:319–26, 309-17. https://doi.org/10.2515/therapie/
2011044.
26. Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S. Missing steps in a
staircase: a qualitative study of the perspectives of key stakeholders on the
use of adaptive designs in confirmatory trials. Trials. 2015;16:430. https://doi.
org/10.1186/s13063-015-0958-9.
27. Dimairo M, Julious SA, Todd S, Nicholl JP, Boote J. Cross-sector surveys
assessing perceptions of key stakeholders towards barriers, concerns and
facilitators to the appropriate use of adaptive designs in confirmatory trials.
Trials. 2015;16:585. https://doi.org/10.1186/s13063-015-1119-x.
28. Meurer WJ, Legocki L, Mawocha S, et al. Attitudes and opinions regarding
confirmatory adaptive clinical trials: a mixed methods analysis from the
adaptive designs accelerating promising trials into treatments (ADAPT-IT)
project. Trials. 2016;17:373. https://doi.org/10.1186/s13063-016-1493-z.
29. Morgan CC, Huyck S, Jenkins M, et al. Adaptive design: results of 2012
survey on perception and use. Ther Innov Regul Sci. 2014;48:473–81.
https://doi.org/10.1177/2168479014522468.
30. Coffey CS, Levin B, Clark C, et al. Overview, hurdles, and future work in
adaptive designs: perspectives from a National Institutes of Health-funded
workshop. Clin Trials. 2012;9:671–80. https://doi.org/10.1177/
1740774512461859.
31. Quinlan J, Gaydos B, Maca J, Krams M. Barriers and opportunities for
implementation of adaptive designs in pharmaceutical product
development. Clin Trials. 2010;7:167–73. https://doi.org/10.1177/
1740774510361542.
32. Coffey CS, Kairalla JA. Adaptive clinical trials: progress and challenges. Drugs
R D. 2008;9:229–42. https://doi.org/10.2165/00126839-200809040-00003.
33. Hartford A, Thomann M, Chen X, et al. Adaptive designs: results of 2016
survey on perception and use. Ther Innov Regul Sci. 2018. https://doi.org/
10.1177/2168479018807715.
34. Chaitman BR, Pepine CJ, Parker JO, Combination Assessment of Ranolazine
In Stable Angina (CARISA) Investigators, et al. Effects of ranolazine with
atenolol, amlodipine, or diltiazem on exercise tolerance and angina
frequency in patients with severe chronic angina: a randomized controlled
trial. JAMA. 2004;291:309–16. https://doi.org/10.1001/jama.291.3.309.
35. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, MUSEC Research
Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
Dimairo et al. Trials          (2020) 21:528 Page 28 of 34
J Neurol Neurosurg Psychiatry. 2012;83:1125–32. https://doi.org/10.1136/
jnnp-2012-302468.
36. Miller E, Gallo P, He W, et al. DIA’s adaptive design scientific working group
(ADSWG): best practices case studies for “less well-understood” adaptive
designs. Ther Innov Regul Sci. 2017;51:77–88. https://doi.org/10.1177/
2168479016665434.
37. Wang S-J, Peng H, Hung HJ. Evaluation of the extent of adaptation to
sample size in clinical trials for cardiovascular and CNS diseases. Contemp
Clin Trials. 2018;67:31–6. https://doi.org/10.1016/j.cct.2018.02.004.
38. Chen YH, Li C, Lan KK. Sample size adjustment based on promising interim
results and its application in confirmatory clinical trials. Clin Trials. 2015;12:
584–95. https://doi.org/10.1177/1740774515594378.
39. Jennison C, Turnbull BW. Adaptive sample size modification in clinical trials:
start small then ask for more? Stat Med. 2015;34:3793–810. https://doi.org/
10.1002/sim.6575.
40. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results
are promising: a practical guide with examples. Stat Med. 2011;30:3267–84.
https://doi.org/10.1002/sim.4102.
41. Chuang-Stein C, Anderson K, Gallo P, et al. Sample size reestimation: a
review and recommendations. Drug Inf J. 2006;40:475–84. https://doi.org/10.
1177/216847900604000413.
42. Friede T, Kieser M. A comparison of methods for adaptive sample size
adjustment. Stat Med. 2001;20:3861–73. https://doi.org/10.1002/sim.972.
43. Friede T, Kieser M. Sample size recalculation for binary data in internal
pilot study designs. Pharm Stat. 2004;3:269–79. https://doi.org/10.1002/
pst.140.
44. Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a
review. Biom J. 2006;48:537–55. https://doi.org/10.1002/bimj.200510238.
45. Stevely A, Dimairo M, Todd S, et al. An investigation of the shortcomings of
the CONSORT 2010 statement for the reporting of group sequential
randomised controlled trials: a methodological systematic review. PLoS One.
2015;10:e0141104. https://doi.org/10.1371/journal.pone.0141104.
46. Pritchett Y, Jemiai Y, Chang Y, et al. The use of group sequential,
information-based sample size re-estimation in the design of the PRIMO
study of chronic kidney disease. Clin Trials. 2011;8:165–74. https://doi.org/10.
1177/1740774511399128.
47. Jennison C, Turnbull BW. Group sequential methods with applications to
clinical trials. London: Chapman & Hall/CRC; 2000.
48. Whitehead J. The design and analysis of sequential clinical trials. 2nd ed.
Hoboken: Wiley; 2000.
49. Mehta CR, Tsiatis AA. Flexible sample size considerations using information-
based interim monitoring. Drug Inf J. 2001;35:1095–112. https://doi.org/10.
1177/009286150103500407.
50. Herson J, Buyse M, Wittes JT. On stopping a randomized clinical trial for
futility. In: Kowalski J, Piantadosi S, editors. Designs for clinical trials:
perspectives on current issues. Berlin: Springer; 2012. p. 109–37. https://doi.
org/10.1007/978-1-4614-0140-7_5.
51. Gallo P, Mao L, Shih VH. Alternative views on setting clinical trial futility
criteria. J Biopharm Stat. 2014;24:976–93. https://doi.org/10.1080/10543406.
2014.932285.
52. Lachin JM. Futility interim monitoring with control of type I and II error
probabilities using the interim Z-value or confidence limit. Clin Trials. 2009;6:
565–73. https://doi.org/10.1177/1740774509350327.
53. Pushpakom SP, Taylor C, Kolamunnage-Dona R, et al. Telmisartan and
insulin resistance in HIV (TAILoR): protocol for a dose-ranging phase II
randomised open-labelled trial of telmisartan as a strategy for the reduction
of insulin resistance in HIV-positive individuals on combination antiretroviral
therapy. BMJ Open. 2015;5:e009566. https://doi.org/10.1136/bmjopen-2015-
009566.
54. Sydes MR, Parmar MKB, Mason MD, et al. Flexible trial design in practice -
stopping arms for lack-of-benefit and adding research arms mid-trial in
STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;
13:168. https://doi.org/10.1186/1745-6215-13-168.
55. Parmar MKB, Barthel FM-S, Sydes M, et al. Speeding up the evaluation of
new agents in cancer. J Natl Cancer Inst. 2008;100:1204–14. https://doi.org/
10.1093/jnci/djn267.
56. Cohen DR, Todd S, Gregory WM, Brown JM. Adding a treatment arm to an
ongoing clinical trial: a review of methodology and practice. Trials. 2015;16:
179. https://doi.org/10.1186/s13063-015-0697-y.
57. Magirr D, Stallard N, Jaki T. Flexible sequential designs for multi-arm clinical
trials. Stat Med. 2014;33:3269–79. https://doi.org/10.1002/sim.6183.
58. Hommel G. Adaptive modifications of hypotheses after an interim analysis.
Biom J. 2001;43:581–9. https://doi.org/10.1002/1521-4036(200109)43:5<581::
AID-BIMJ581>3.0.CO;2-J.
59. Jaki T. Multi-arm clinical trials with treatment selection: what can be gained
and at what price? Clin Investig (Lond). 2015;5:393–9. https://doi.org/10.
4155/cli.15.13.
60. Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm
multi-stage trials. Stat Methods Med Res. 2016;25:716–27. https://doi.org/10.
1177/0962280212465498.
61. Wason J, Stallard N, Bowden J, Jennison C. A multi-stage drop-the-losers
design for multi-arm clinical trials. Stat Methods Med Res. 2017;26:508–24.
https://doi.org/10.1177/0962280214550759.
62. Ghosh P, Liu L, Senchaudhuri P, Gao P, Mehta C. Design and monitoring of
multi-arm multi-stage clinical trials. Biometrics. 2017;73:1289–99. https://doi.
org/10.1111/biom.12687.
63. Heritier S, Lô SN, Morgan CC. An adaptive confirmatory trial with interim
treatment selection: practical experiences and unbalanced randomization.
Stat Med. 2011;30:1541–54. https://doi.org/10.1002/sim.4179.
64. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing
and estimation in flexible group sequential designs with adaptive treatment
selection. Stat Med. 2005;24:3697–714. https://doi.org/10.1002/sim.2389.
65. Bauer P, Kieser M. Combining different phases in the development of
medical treatments within a single trial. Stat Med. 1999;18:1833–48.
https://doi.org/10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-
SIM221>3.0.CO;2-3.
66. Bretz F, Koenig F, Brannath W, Glimm E, Posch M. Adaptive designs for
confirmatory clinical trials. Stat Med. 2009;28:1181–217. https://doi.org/10.
1002/sim.3538.
67. Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of
idarubicin and cytarabine versus troxacitabine and cytarabine versus
troxacitabine and idarubicin in untreated patients 50 years or older with
adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003;21:1722–7.
https://doi.org/10.1200/JCO.2003.11.016.
68. Grieve AP. Response-adaptive clinical trials: case studies in the medical
literature. Pharm Stat. 2017;16:64–86. https://doi.org/10.1002/pst.1778.
69. Hu F, Rosenberger WF. The theory of response-adaptive randomization in
clinical trials. Wiley: Hoboken, 2006 doi:https://doi.org/10.1002/047005588X.
70. Nowacki AS, Zhao W, Palesch YY. A surrogate-primary replacement
algorithm for response-adaptive randomization in stroke clinical trials. Stat
Methods Med Res. 2017;26:1078–92. https://doi.org/10.1177/
0962280214567142.
71. Eickhoff JC, Kim K, Beach J, Kolesar JM, Gee JR. A Bayesian adaptive design
with biomarkers for targeted therapies. Clin Trials. 2010;7:546–56. https://doi.
org/10.1177/1740774510372657.
72. Williamson SF, Jacko P, Villar SS, Jaki T. A Bayesian adaptive design for
clinical trials in rare diseases. Comput Stat Data Anal. 2017;113:136–53.
https://doi.org/10.1016/j.csda.2016.09.006.
73. Berry DA, Eick SG. Adaptive assignment versus balanced randomization in
clinical trials: a decision analysis. Stat Med. 1995;14:231–46. https://doi.org/
10.1002/sim.4780140302.
74. Chen YH, Gesser R, Luxembourg A. A seamless phase IIB/III adaptive
outcome trial: design rationale and implementation challenges. Clin Trials.
2015;12:84–90. https://doi.org/10.1177/1740774514552110.
75. Cuffe RL, Lawrence D, Stone A, Vandemeulebroecke M. When is a seamless
study desirable? Case studies from different pharmaceutical sponsors.
Pharm Stat. 2014;13:229–37. https://doi.org/10.1002/pst.1622.
76. Donohue JF, Fogarty C, Lötvall J, INHANCE Study Investigators, et al. Once-
daily bronchodilators for chronic obstructive pulmonary disease: indacaterol
versus tiotropium. Am J Respir Crit Care Med. 2010;182:155–62. https://doi.
org/10.1164/rccm.200910-1500OC.
77. Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless
phase II/III clinical trials with hypotheses selection at interim: general
concepts. Biom J. 2006;48:623–34. https://doi.org/10.1002/bimj.200510232.
78. Bauer P, Bretz F, Dragalin V, König F, Wassmer G. Twenty-five years of
confirmatory adaptive designs: opportunities and pitfalls. Stat Med. 2016;35:
325–47. https://doi.org/10.1002/sim.6472.
79. Koenig F, Brannath W, Bretz F, Posch M. Adaptive Dunnett tests for treatment
selection. Stat Med. 2008;27:1612–25. https://doi.org/10.1002/sim.3048.
80. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-guided
adaptive trial designs in phase II and phase III: a methodological review.
PLoS One. 2016;11:e0149803. https://doi.org/10.1371/journal.pone.0149803.
Dimairo et al. Trials          (2020) 21:528 Page 29 of 34
81. Liu S, Lee JJ. An overview of the design and conduct of the BATTLE trials. Chin
Clin Oncol. 2015;4:33. https://doi.org/10.3978/j.issn.2304-3865.2015.06.07.
82. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2:
an adaptive breast cancer trial design in the setting of neoadjuvant
chemotherapy. Clin Pharmacol Ther. 2009;86:97–100. https://doi.org/10.
1038/clpt.2009.68.
83. Renfro LA, Mallick H, An MW, Sargent DJ, Mandrekar SJ. Clinical trial designs
incorporating predictive biomarkers. Cancer Treat Rev. 2016;43:74–82.
https://doi.org/10.1016/j.ctrv.2015.12.008.
84. Ondra T, Dmitrienko A, Friede T, et al. Methods for identification and
confirmation of targeted subgroups in clinical trials: a systematic review. J
Biopharm Stat. 2016;26:99–119. https://doi.org/10.1080/10543406.2015.
1092034.
85. Chiu Y-D, Koenig F, Posch M, Jaki T. Design and estimation in clinical trials
with subpopulation selection. Stat Med. 2018;37:4335–52. https://doi.org/10.
1002/sim.7925.
86. Graf AC, Wassmer G, Friede T, Gera RG, Posch M. Robustness of testing
procedures for confirmatory subpopulation analyses based on a continuous
biomarker. Stat Methods Med Res. 2019;28:1879–92. https://doi.org/10.1177/
0962280218777538.
87. Joshi A, Zhang J, Fang L. Statistical design for a confirmatory trial with a
continuous predictive biomarker: a case study. Contemp Clin Trials. 2017;63:
19–29. https://doi.org/10.1016/j.cct.2017.05.010.
88. Wang SJ, Hung HMJ. Adaptive enrichment with subpopulation selection at
interim: methodologies, applications and design considerations. Contemp
Clin Trials. 2013;36:673–81. https://doi.org/10.1016/j.cct.2013.09.008.
89. Hünseler C, Balling G, Röhlig C, Clonidine Study Group, et al. Continuous
infusion of clonidine in ventilated newborns and infants: a randomized
controlled trial. Pediatr Crit Care Med. 2014;15:511–22. https://doi.org/10.
1097/PCC.0000000000000151.
90. Hommel G, Kropf S. Clinical trials with an adaptive choice of hypotheses.
Drug Inf J. 2001;35:1423–9. https://doi.org/10.1177/009286150103500438.
91. Branson M, Whitehead J. Estimating a treatment effect in survival studies in
which patients switch treatment. Stat Med. 2002;21:2449–63. https://doi.org/
10.1002/sim.1219.
92. Shao J, Chang M, Chow S-C. Statistical inference for cancer trials with
treatment switching. Stat Med. 2005;24:1783–90. https://doi.org/10.1002/sim.
2128.
93. Skrivanek Z, Gaydos BL, Chien JY, et al. Dose-finding results in an adaptive,
seamless, randomized trial of once-weekly dulaglutide combined with
metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab.
2014;16:748–56. https://doi.org/10.1111/dom.12305.
94. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized,
controlled trial of oral propranolol in infantile hemangioma. N Engl J Med.
2015;372:735–46. https://doi.org/10.1056/NEJMoa1404710.
95. Mehta CR, Liu L, Theuer C. An adaptive population enrichment phase III trial
of TRC105 and pazopanib versus pazopanib alone in patients with
advanced angiosarcoma (TAPPAS trial). Ann Oncol. 2019;30:103–8. https://
doi.org/10.1093/annonc/mdy464.
96. Nogueira RG, Jadhav AP, Haussen DC, DAWN Trial Investigators, et al.
Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit
and infarct. N Engl J Med. 2018;378:11–21. https://doi.org/10.1056/
NEJMoa1706442.
97. Collignon O, Koenig F, Koch A, et al. Adaptive designs in clinical trials: from
scientific advice to marketing authorisation to the European medicine
agency. Trials. 2018;19:642. https://doi.org/10.1186/s13063-018-3012-x.
98. Lewis RJ, Angus DC, Laterre PF, Selepressin Evaluation Programme for
Sepsis-induced Shock-Adaptive Clinical Trial, et al. Rationale and design of
an adaptive phase 2b/3 clinical trial of selepressin for adults in septic shock:
selepressin evaluation programme for sepsis-induced shock - adaptive
clinical trial. Ann Am Thorac Soc. 2018;15:250–7. https://doi.org/10.1513/
AnnalsATS.201708-669SD.
99. Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential
clinical trials. Biometrics. 1999;55:853–7. https://doi.org/10.1111/j.0006-341X.
1999.00853.x.
100. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for
oncology trials with subpopulation selection using correlated survival
endpoints. Pharm Stat. 2011;10:347–56. https://doi.org/10.1002/pst.472.
101. Wason JMS, Abraham JE, Baird RD, et al. A Bayesian adaptive design for
biomarker trials with linked treatments. Br J Cancer. 2015;113:699–705.
https://doi.org/10.1038/bjc.2015.278.
102. Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the
future. Clin Trials. 2016;13:358–66. https://doi.org/10.1177/
1740774515626362.
103. Phillips AJ, Keene ON, PSI Adaptive Design Expert Group. Adaptive designs
for pivotal trials: discussion points from the PSI adaptive design expert
group. Pharm Stat. 2006;5:61–6. https://doi.org/10.1002/pst.206.
104. Rong Y. Regulations on adaptive design clinical trials. Pharm Regul Aff. 2014;
3. https://doi.org/10.4172/2167-7689.1000116.
105. Bauer P, Brannath W. The advantages and disadvantages of adaptive
designs for clinical trials. Drug Discov Today. 2004;9:351–7. https://doi.org/
10.1016/S1359-6446(04)03023-5.
106. Huskins WC, Fowler VG Jr, Evans S. Adaptive designs for clinical trials:
application to healthcare epidemiology research. Clin Infect Dis. 2018;66:
1140–6. https://doi.org/10.1093/cid/cix907.
107. Bauer P, Einfalt J. Application of adaptive designs--a review. Biom J. 2006;48:
493–506. https://doi.org/10.1002/bimj.200510204.
108. Elsäßer A, Regnstrom J, Vetter T, et al. Adaptive clinical trial designs for
European marketing authorization: a survey of scientific advice letters from
the European medicines agency. Trials. 2014;15:383. https://doi.org/10.1186/
1745-6215-15-383.
109. Food and Drug Administration. Guidance for industry: adaptive design
clinical trials for drugs and biologics. 2010. https://www.fda.gov/downloads/
Drugs/.../Guidances/ucm201790.pdf.
110. CHMP. Reflection paper on methodological issues in confirmatory
clinical trials planned with an adaptive design. 2007. https://www.ema.
europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/
WC500003616.pdf.
111. Food and Drug Administration. Adaptive designs for clinical trials of drugs
and biologics: guidance for industry. 2019. https://www.fda.gov/media/784
95/download.
112. Yang X, Thompson L, Chu J, et al. Adaptive design practice at the Center
for Devices and Radiological Health (CDRH), January 2007 to May 2013. Ther
Innov Regul Sci. 2016;50:710–7. https://doi.org/10.1177/2168479016656027.
113. Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design
methodology within the field of oncology in randomised controlled trials
and a proposed extension to the CONSORT guidelines. BMC Med Res
Methodol. 2017;17:108. https://doi.org/10.1186/s12874-017-0393-6.
114. Hatfield I, Allison A, Flight L, Julious SA, Dimairo M. Adaptive designs
undertaken in clinical research: a review of registered clinical trials. Trials.
2016;17:150. https://doi.org/10.1186/s13063-016-1273-9.
115. Sato A, Shimura M, Gosho M. Practical characteristics of adaptive design in
phase 2 and 3 clinical trials. J Clin Pharm Ther. 2018;43:170–80. https://doi.
org/10.1111/jcpt.12617.
116. Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials:
a review of the literature and ClinicalTrials.gov. BMJ Open. 2018;8:e018320.
https://doi.org/10.1136/bmjopen-2017-018320.
117. Gosho M, Sato Y, Nagashima K, Takahashi S. Trends in study design and the
statistical methods employed in a leading general medicine journal. J Clin
Pharm Ther. 2018;43:36–44. https://doi.org/10.1111/jcpt.12605.
118. Cerqueira FP, Jesus AMC, Cotrim MD. Adaptive design: a review of the
technical, statistical, and regulatory aspects of implementation in a clinical
trial. Ther Innov Regul Sci. 2019. https://doi.org/10.1177/2168479019831240.
119. Lin M, Lee S, Zhen B, et al. CBER’s experience with adaptive design clinical
trials. Ther Innov Regul Sci. 2016;50:195–203. https://doi.org/10.1177/
2168479015604181.
120. Dimairo M. The utility of adaptive designs in publicly funded confirmatory
trials. 2016. http://etheses.whiterose.ac.uk/13981/1/DimairoPhDThesis2016
WhiteRoseSubmission.pdf.
121. Detry MA, Lewis RJ, Broglio KR, et al. Standards for the design, conduct, and
evaluation of adaptive randomized clinical trials. 2012. https://www.pcori.
org/assets/Standards-for-the-Design-Conduct-and-Evaluation-of-Adaptive-
Randomized-Clinical-Trials.pdf.
122. Campbell G. Similarities and differences of Bayesian designs and adaptive
designs for medical devices: a regulatory view. Stat Biopharm Res. 2013;5:
356–68. https://doi.org/10.1080/19466315.2013.846873.
123. Gaydos B, Anderson KM, Berry D, et al. Good practices for adaptive clinical
trials in pharmaceutical product development. Ther Innov Regul Sci. 2009;
43:539–56. https://doi.org/10.1177/009286150904300503.
124. Chow S-C, Chang M, Pong A. Statistical consideration of adaptive methods
in clinical development. J Biopharm Stat. 2005;15:575–91. https://doi.org/10.
1081/BIP-200062277.
Dimairo et al. Trials          (2020) 21:528 Page 30 of 34
125. Chow S-C, Corey R. Benefits, challenges and obstacles of adaptive clinical
trial designs. Orphanet J Rare Dis. 2011;6:79. https://doi.org/10.1186/1750-
1172-6-79.
126. Quinlan J, Krams M. Implementing adaptive designs: logistical and
operational considerations. Drug Inf J. 2006;40:437–44. https://doi.org/10.
1177/216847900604000409.
127. Wang SJ. Perspectives on the use of adaptive designs in clinical trials. Part I.
statistical considerations and issues. J Biopharm Stat. 2010;20:1090–7.
https://doi.org/10.1080/10543406.2010.514446.
128. Dimairo M, Todd S, Julious S, et al. ACE project protocol version 2.3:
development of a CONSORT Extension for adaptive clinical trials: EQUATOR
Netw; 2016. https://www.equator-network.org/wp-content/uploads/201
7/12/ACE-Project-Protocol-v2.3.pdf.
129. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health
research reporting guidelines. PLoS Med. 2010;7:e1000217. https://doi.org/
10.1371/journal.pmed.1000217.
130. Rosenberg MJ. The agile approach to adaptive research: optimizing
efficiency in clinical development. 1st ed. Hoboken: Wiley; 2010. https://doi.
org/10.1002/9780470599686.
131. Avery KNL, Williamson PR, Gamble C, Members of the Internal Pilot Trials
Workshop supported by the Hubs for Trials Methodology Research, et al.
Informing efficient randomised controlled trials: exploration of challenges in
developing progression criteria for internal pilot studies. BMJ Open. 2017;7:
e013537. https://doi.org/10.1136/bmjopen-2016-013537.
132. Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of multi-arm
parallel-group randomized trials: extension of the CONSORT 2010
statement. JAMA. 2019;321:1610–20. https://doi.org/10.1001/jama.2019.3087.
133. Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT Group.
Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;
345:e5661. https://doi.org/10.1136/bmj.e5661.
134. Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension
to randomised crossover trials. BMJ. 2019;366:l4378. https://doi.org/10.1136/
bmj.l4378.
135. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, CONSORT Group.
Reporting of noninferiority and equivalence randomized trials: extension of
the CONSORT 2010 statement. JAMA. 2012;308:2594–604. https://doi.org/10.
1001/jama.2012.87802.
136. Hopewell S, Clarke M, Moher D, CONSORT Group, et al. CONSORT for
reporting randomized controlled trials in journal and conference abstracts:
explanation and elaboration. PLoS Med. 2008;5:e20. https://doi.org/10.1371/
journal.pmed.0050020.
137. Hopewell S, Clarke M, Moher D, CONSORT Group, et al. CONSORT for
reporting randomised trials in journal and conference abstracts. Lancet.
2008;371:281–3. https://doi.org/10.1016/S0140-6736(07)61835-2.
138. Ioannidis JPA, Evans SJW, Gøtzsche PC, CONSORT Group, et al. Better
reporting of harms in randomized trials: an extension of the CONSORT
statement. Ann Intern Med. 2004;141:781–8. https://doi.org/10.7326/0003-
4819-141-10-200411160-00009.
139. MEDLINE. Adaptive clinical trial MeSH descriptor data 2019. 2019. https://
meshb.nlm.nih.gov/record/ui?ui=D000076362.
140. Backonja M, Williams L, Miao X, Katz N, Chen C. Safety and efficacy of
neublastin in painful lumbosacral radiculopathy: a randomized, double-
blinded, placebo-controlled phase 2 trial using Bayesian adaptive design
(the SPRINT trial). Pain. 2017;158:1802–12. https://doi.org/10.1097/j.pain.
0000000000000983.
141. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose
selection in a clinical study in COPD using an adaptive seamless design.
Pulm Pharmacol Ther. 2010;23:165–71. https://doi.org/10.1016/j.pupt.2010.
01.003.
142. Jones AE, Puskarich MA, Shapiro NI, et al. Effect of levocarnitine vs placebo
as an adjunctive treatment for septic shock: the rapid Administration of
Carnitine in Sepsis (RACE) randomized clinical Trial. JAMA Netw Open. 2018;
1:e186076. https://doi.org/10.1001/jamanetworkopen.2018.6076.
143. Khalil EAG, Weldegebreal T, Younis BM, et al. Safety and efficacy of single
dose versus multiple doses of AmBisome for treatment of visceral
leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis. 2014;
8:e2613. https://doi.org/10.1371/journal.pntd.0002613.
144. Steg PG, Mehta SR, Pollack CV Jr, TAO Investigators, et al. Anticoagulation
with otamixaban and ischemic events in non-ST-segment elevation acute
coronary syndromes: the TAO randomized clinical trial. JAMA. 2013;310:
1145–55. https://doi.org/10.1001/jama.2013.277165.
145. McMurray JJV, Packer M, Desai AS, PARADIGM-HF Investigators and
Committees, et al. Angiotensin-neprilysin inhibition versus enalapril in heart
failure. N Engl J Med. 2014;371:993–1004. https://doi.org/10.1056/
NEJMoa1409077.
146. Rosenblum M, Hanley DF. Adaptive enrichment designs for stroke clinical
trials. Stroke. 2017;48:2021–5. https://doi.org/10.1161/STROKEAHA.116.
015342.
147. Lachin JM. A review of methods for futility stopping based on conditional
power. Stat Med. 2005;24:2747–64. https://doi.org/10.1002/sim.2151.
148. Proschan M, Lan KKG, Wittes JT. Power: conditional, unconditional, and
predictive. In: Statistical monitoring of clinical trials - a unified approach.
Berlin: Springer; 2006. p. 43–66.
149. Lan KG, Simon R, Halperin M. Stochastically curtailed tests in long–term
clinical trials. Seq Anal. 1982;1:37–41. https://doi.org/10.1080/
07474948208836014.
150. Bauer P, Koenig F. The reassessment of trial perspectives from interim data--
a critical view. Stat Med. 2006;25:23–36. https://doi.org/10.1002/sim.2180.
151. Herson J. Predictive probability early termination plans for phase II clinical
trials. Biometrics. 1979;35:775–83. https://doi.org/10.2307/2530109.
152. Choi SC, Pepple PA. Monitoring clinical trials based on predictive
probability of significance. Biometrics. 1989;45:317–23. https://doi.org/10.
2307/2532056.
153. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials:
conditional or predictive power? Control Clin Trials. 1986;7:8–17. https://doi.
org/10.1016/0197-2456(86)90003-6.
154. Skrivanek Z, Berry S, Berry D, et al. Application of adaptive design
methodology in development of a long-acting glucagon-like peptide-1
analog (dulaglutide): statistical design and simulations. J Diabetes Sci
Technol. 2012;6:1305–18. https://doi.org/10.1177/193229681200600609.
155. Ouellet D. Benefit-risk assessment: the use of clinical utility index. Expert
Opin Drug Saf. 2010;9:289–300. https://doi.org/10.1517/14740330903499265.
156. Thadhani R, Appelbaum E, Chang Y, et al. Vitamin D receptor activation and
left ventricular hypertrophy in advanced kidney disease. Am J Nephrol.
2011;33:139–49. https://doi.org/10.1159/000323551.
157. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac
structure and function in patients with chronic kidney disease: the PRIMO
randomized controlled trial. JAMA. 2012;307:674–84. https://doi.org/10.1001/
jama.2012.120.
158. Gould AL, Shih WJ. Sample size re-estimation without unblinding for
normally distributed outcomes with unknown variance. Commun Stat
Theory Methods. 1992;21:2833–53. https://doi.org/10.1080/
03610929208830947.
159. Gould AL. Planning and revising the sample size for a trial. Stat Med. 1995;
14:1039–51, discussion 1053-5. https://doi.org/10.1002/sim.4780140922.
160. Kieser M, Friede T. Blinded sample size reestimation in multiarmed clinical
trials. Drug Inf J. 2000;34:455–60. https://doi.org/10.1177/
009286150003400214.
161. Posch M, Proschan MA. Unplanned adaptations before breaking the blind.
Stat Med. 2012;31:4146–53. https://doi.org/10.1002/sim.5361.
162. Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy
increases the efficiency of clinical trials in secondary progressive multiple
sclerosis. Mult Scler. 2011;17:81–8. https://doi.org/10.1177/
1352458510382129.
163. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials.
Stat Med. 2012;31:2973–84. https://doi.org/10.1002/sim.5403.
164. Heatley G, Sood P, Goldstein D, MOMENTUM 3 Investigators, et al. Clinical
trial design and rationale of the Multicenter Study of MagLev Technology in
Patients Undergoing Mechanical Circulatory Support Therapy with
HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study
protocol. J Heart Lung Transplant. 2016;35:528–36. https://doi.org/10.1016/j.
healun.2016.01.021.
165. Barrington P, Chien JY, Showalter HDH, et al. A 5-week study of the
pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-
acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
Diabetes Obes Metab. 2011;13:426–33. https://doi.org/10.1111/j.1463-1326.
2011.01364.x.
166. Geiger MJ, Skrivanek Z, Gaydos B, Chien J, Berry S, Berry D. An adaptive,
dose-finding, seamless phase 2/3 study of a long-acting glucagon-like
peptide-1 analog (dulaglutide): trial design and baseline characteristics. J
Diabetes Sci Technol. 2012;6:1319–27. https://doi.org/10.1177/
193229681200600610.
Dimairo et al. Trials          (2020) 21:528 Page 31 of 34
167. James ND, Sydes MR, Mason MD, STAMPEDE investigators, et al. Celecoxib
plus hormone therapy versus hormone therapy alone for hormone-sensitive
prostate cancer: first results from the STAMPEDE multiarm, multistage,
randomised controlled trial. Lancet Oncol. 2012;13:549–58. https://doi.org/
10.1016/S1470-2045(12)70088-8.
168. Dwan K, Kirkham JJ, Williamson PR, Gamble C. Selective reporting of outcomes
in randomised controlled trials in systematic reviews of cystic fibrosis. BMJ
Open. 2013;3:e002709. https://doi.org/10.1136/bmjopen-2013-002709.
169. Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical
evidence of study publication bias and outcome reporting bias. PLoS One.
2008;3:e3081. https://doi.org/10.1371/journal.pone.0003081.
170. Lancee M, Lemmens CMC, Kahn RS, Vinkers CH, Luykx JJ. Outcome
reporting bias in randomized-controlled trials investigating antipsychotic
drugs. Transl Psychiatry. 2017;7:e1232. https://doi.org/10.1038/tp.2017.
203.
171. Evans S. When and how can endpoints be changed after initiation of a
randomized clinical trial? PLoS Clin Trials. 2007;2:e18. https://doi.org/10.
1371/journal.pctr.0020018.
172. Wason JMS, Mander AP, Thompson SG. Optimal multistage designs for
randomised clinical trials with continuous outcomes. Stat Med. 2012;31:301–
12. https://doi.org/10.1002/sim.4421.
173. Wason JMS, Mander AP. Minimizing the maximum expected sample size in
two-stage phase II clinical trials with continuous outcomes. J Biopharm Stat.
2012;22:836–52. https://doi.org/10.1080/10543406.2010.528104.
174. Cook JA, Julious SA, Sones W, et al. DELTA2 guidance on choosing the
target difference and undertaking and reporting the sample size calculation
for a randomised controlled trial. BMJ. 2018;363:k3750. https://doi.org/10.
1136/bmj.k3750.
175. Bell ML. New guidance to improve sample size calculations for trials:
eliciting the target difference. Trials. 2018;19:605. https://doi.org/10.1186/
s13063-018-2894-y.
176. Dunnett C. Selection of the best treatment in comparison to a control with
an application to a medical trial. In: Santer T, Tamhane A, editors. Design of
experiments : ranking and selection. New York: Marcel Dekker; 1984. p. 47–
66. https://books.google.co.uk/books?id=1Un6FKdqUg4C&printsec=
frontcover#v=onepage&q&f=false.
177. Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for multi-arm
multi-stage clinical studies with treatment selection. Biometrika. 2012;99:
494–501. https://doi.org/10.1093/biomet/ass002.
178. Whitehead J, Jaki T. One- and two-stage design proposals for a phase II
trial comparing three active treatments with control using an ordered
categorical endpoint. Stat Med. 2009;28:828–47. https://doi.org/10.1002/
sim.3508.
179. Jaki T, Magirr D. Designing multi-arm multi-stage studies: R Package ‘MAMS’;
2014.
180. Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of
type I error probability spending functions. Stat Med. 1990;9:1439–45.
https://doi.org/10.1002/sim.4780091207.
181. Steg PG, Mehta SR, Pollack CV Jr, et al. Design and rationale of the
treatment of acute coronary syndromes with otamixaban trial: a double-
blind triple-dummy 2-stage randomized trial comparing otamixaban to
unfractionated heparin and eptifibatide in non-ST-segment elevation acute
coronary syndromes with a planned early invasive strategy. Am Heart J.
2012;164:817–24.e13. https://doi.org/10.1016/j.ahj.2012.10.001.
182. Du Y, Wang X, Jack LJ. Simulation study for evaluating the performance of
response-adaptive randomization. Contemp Clin Trials. 2015;40:15–25.
https://doi.org/10.1016/j.cct.2014.11.006.
183. Lorch U, O’Kane M, Taubel J. Three steps to writing adaptive study
protocols in the early phase clinical development of new medicines. BMC
Med Res Methodol. 2014;14:84. https://doi.org/10.1186/1471-2288-14-84.
184. Guetterman TC, Fetters MD, Legocki LJ, et al. Reflections on the adaptive
designs accelerating promising trials into treatments (ADAPT-IT) process-
findings from a qualitative study. Clin Res Regul Aff. 2015;32:121–30. https://
doi.org/10.3109/10601333.2015.1079217.
185. Pocock SJ. Group sequential methods in the design and analysis of clinical
trials. Biometrika. 1977;64:191. https://doi.org/10.1093/biomet/64.2.191.
186. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials.
Biometrics. 1979;35:549–56. https://doi.org/10.2307/2530245.
187. Gsponer T, Gerber F, Bornkamp B, Ohlssen D, Vandemeulebroecke M,
Schmidli H. A practical guide to Bayesian group sequential designs. Pharm
Stat. 2014;13:71–80. https://doi.org/10.1002/pst.1593.
188. Emerson SS, Kittelson JM, Gillen DL. Frequentist evaluation of group
sequential clinical trial designs. Stat Med. 2007;26:5047–80. https://doi.org/
10.1002/sim.2901.
189. Togo K, Iwasaki M. Optimal timing for interim analyses in clinical trials. J
Biopharm Stat. 2013;23:1067–80. https://doi.org/10.1080/10543406.2013.
813522.
190. Xi D, Gallo P, Ohlssen D. On the optimal timing of futility interim analyses.
Stat Biopharm Res. 2017;9:293–301. https://doi.org/10.1080/19466315.2017.
1340906.
191. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery
compared with surgery alone for localized esophageal cancer. N Engl J
Med. 1998;339:1979–84. https://doi.org/10.1056/NEJM199812313392704.
192. Medical Research Council Oesophageal Cancer Working Group. Surgical
resection with or without preoperative chemotherapy in oesophageal
cancer: a randomised controlled trial. Lancet. 2002;359:1727–33. https://doi.
org/10.1016/S0140-6736(02)08651-8.
193. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses.
Biometrics. 1994;50:1029–41. https://doi.org/10.2307/2533441.
194. Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy
versus chemoradiotherapy in locally advanced adenocarcinomas of the
oesophagogastric junction (POET): long-term results of a controlled
randomised trial. Eur J Cancer. 2017;81:183–90. https://doi.org/10.1016/j.ejca.
2017.04.027.
195. Pocock SJ, Clayton TC, Stone GW. Challenging issues in clinical trial design:
part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol.
2015;66:2886–98. https://doi.org/10.1016/j.jacc.2015.10.051.
196. Jansen JO, Pallmann P, MacLennan G, Campbell MK, UK-REBOA Trial
Investigators. Bayesian clinical trial designs: another option for trauma trials?
J Trauma Acute Care Surg. 2017;83:736–41. https://doi.org/10.1097/TA.
0000000000001638.
197. Jiang Y, Zhao W, Durkalski-Mauldin V. Impact of adaptation algorithm,
timing, and stopping boundaries on the performance of Bayesian
response adaptive randomization in confirmative trials with a binary
endpoint. Contemp Clin Trials. 2017;62:114–20. https://doi.org/10.1016/j.
cct.2017.08.019.
198. Chappell R, Durkalski V, Joffe S. University of Pennsylvania ninth annual
conference on statistical issues in clinical trials: where are we with adaptive
clinical trial designs? (morning panel discussion). Clin Trials. 2017;14:441–50.
https://doi.org/10.1177/1740774517723590.
199. Brown CH, Ten Have TR, Jo B, et al. Adaptive designs for randomized trials
in public health. Annu Rev Public Health. 2009;30:1–25. https://doi.org/10.
1146/annurev.publhealth.031308.100223.
200. Fleming TR, Sharples K, McCall J, Moore A, Rodgers A, Stewart R.
Maintaining confidentiality of interim data to enhance trial integrity and
credibility. Clin Trials. 2008;5:157–67. https://doi.org/10.1177/
1740774508089459.
201. He W, Gallo P, Miller E, et al. Addressing challenges and opportunities of
“less well-understood” adaptive designs. Ther Innov Regul Sci. 2017;51:60–8.
https://doi.org/10.1177/2168479016663265.
202. Husten L. Orexigen released interim data without approval of trial
leaders: Forbes; 2015. https://www.forbes.com/sites/larryhusten/2015/03/
03/orexigen-released-interim-data-without-approval-of-trial-leaders/#74a03
0de4aef.
203. Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug
Inf J. 2006;40:445–50. https://doi.org/10.1177/216847900604000410.
204. Chow S-C, Corey R, Lin M. On the independence of data monitoring
committee in adaptive design clinical trials. J Biopharm Stat. 2012;22:853–67.
https://doi.org/10.1080/10543406.2012.676536.
205. Herson J. Coordinating data monitoring committees and adaptive clinical
trial designs. Drug Inf J. 2008;42:297–301. https://doi.org/10.1177/
009286150804200401.
206. Akacha M, Bretz F, Ohlssen D, et al. Estimands and their role in clinical trials.
Stat Biopharm Res. 2017;9:268–71. https://doi.org/10.1080/19466315.2017.
1302358.
207. Akacha M, Bretz F, Ruberg S. Estimands in clinical trials - broadening the
perspective. Stat Med. 2017;36:5–19. https://doi.org/10.1002/sim.7033.
208. Gu X, Chen N, Wei C, et al. Bayesian two-stage biomarker-based adaptive
design for targeted therapy development. Stat Biosci. 2016;8:99–128. https://
doi.org/10.1007/s12561-014-9124-2.
209. Wittes J. Stopping a trial early - and then what? Clin Trials. 2012;9:714–20.
https://doi.org/10.1177/1740774512454600.
Dimairo et al. Trials          (2020) 21:528 Page 32 of 34
210. Bassler D, Briel M, Montori VM, STOPIT-2 Study Group, et al. Stopping
randomized trials early for benefit and estimation of treatment effects:
systematic review and meta-regression analysis. JAMA. 2010;303:1180–7.
https://doi.org/10.1001/jama.2010.310.
211. Wears RL. Are we there yet? Early stopping in clinical trials. Ann Emerg Med.
2015;65:214–5. https://doi.org/10.1016/j.annemergmed.2014.12.020.
212. Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical
trials. Stat Med. 1988;7:1231–42. https://doi.org/10.1002/sim.4780071204.
213. Pocock SJ, Hughes MD. Practical problems in interim analyses, with
particular regard to estimation. Control Clin Trials. 1989;10(Suppl):209S–21S.
https://doi.org/10.1016/0197-2456(89)90059-7.
214. Walter SD, Han H, Briel M, Guyatt GH. Quantifying the bias in the estimated
treatment effect in randomized trials having interim analyses and a rule for
early stopping for futility. Stat Med. 2017;36:1506–18. https://doi.org/10.
1002/sim.7242.
215. Wang H, Rosner GL, Goodman SN. Quantifying over-estimation in early
stopped clinical trials and the “freezing effect” on subsequent research. Clin
Trials. 2016;13:621–31. https://doi.org/10.1177/1740774516649595.
216. Freidlin B, Korn EL. Stopping clinical trials early for benefit: impact on
estimation. Clin Trials. 2009;6:119–25. https://doi.org/10.1177/
1740774509102310.
217. Bauer P, Koenig F, Brannath W, Posch M. Selection and bias--two hostile
brothers. Stat Med. 2010;29:1–13. https://doi.org/10.1002/sim.3716.
218. Walter SD, Guyatt GH, Bassler D, Briel M, Ramsay T, Han HD. Randomised
trials with provision for early stopping for benefit (or harm): the impact on
the estimated treatment effect. Stat Med. 2019;38:2524–43. https://doi.org/
10.1002/sim.8142.
219. Flight L, Arshad F, Barnsley R, et al. A review of clinical trials with an
adaptive design and health economic analysis. Value Health. 2019;22:391–8.
https://doi.org/10.1016/j.jval.2018.11.008.
220. Whitehead J. Supplementary analysis at the conclusion of a sequential
clinical trial. Biometrics. 1986;42:461–71. https://doi.org/10.2307/2531197.
221. Cameron C, Ewara E, Wilson FR, et al. The importance of considering
differences in study design in network meta-analysis: an application using
anti-tumor necrosis factor drugs for ulcerative colitis. Med Decis Mak. 2017;
37:894–904. https://doi.org/10.1177/0272989X17711933.
222. Mehta CR, Bauer P, Posch M, Brannath W. Repeated confidence intervals for
adaptive group sequential trials. Stat Med. 2007;26:5422–33. https://doi.org/
10.1002/sim.3062.
223. Brannath W, König F, Bauer P. Estimation in flexible two stage designs. Stat
Med. 2006;25:3366–81. https://doi.org/10.1002/sim.2258.
224. Brannath W, Mehta CR, Posch M. Exact confidence bounds following
adaptive group sequential tests. Biometrics. 2009;65:539–46. https://doi.org/
10.1111/j.1541-0420.2008.01101.x.
225. Gao P, Liu L, Mehta C. Exact inference for adaptive group sequential
designs. Stat Med. 2013;32:3991–4005. https://doi.org/10.1002/sim.5847.
226. Kunzmann K, Benner L, Kieser M. Point estimation in adaptive enrichment
designs. Stat Med. 2017;36:3935–47. https://doi.org/10.1002/sim.7412.
227. Jennison C, Turnbull BW. Analysis following a sequential test. In: Group
sequential methods with applications to clinical trials: Chapman & Hall/CRC;
2000. p. 171–87.
228. Heritier S, Lloyd CJ, Lô SN. Accurate p-values for adaptive designs
with binary endpoints. Stat Med. 2017;36:2643–55. https://doi.org/10.
1002/sim.7324.
229. Simon R, Simon N. Inference for multimarker adaptive enrichment trials. Stat
Med. 2017;36:4083–93. https://doi.org/10.1002/sim.7422.
230. Kunz CU, Jaki T, Stallard N. An alternative method to analyse the biomarker-
strategy design. Stat Med. 2018;37:4636–51. https://doi.org/10.1002/sim.
7940.
231. Hack N, Brannath W. Estimation in adaptive group sequential trials; 2011.
232. Zhu L, Ni L, Yao B. Group sequential methods and software applications.
Am Stat. 2011;65:127–35. https://doi.org/10.1198/tast.2011.10213.
233. Tymofyeyev Y. A review of available software and capabilities for adaptive
designs. In: Practical considerations for adaptive trial design and
implementation. Berlin: Springer; 2014. p. 139–55. https://doi.org/10.1007/
978-1-4939-1100-4_8.
234. Hack N, Brannath W, Brueckner M. AGSDest: estimation in adaptive
group sequential trials. 2019. https://cran.r-project.org/web/packages/
AGSDest/.
235. Fernandes RM, van der Lee JH, Offringa M. A systematic review of the
reporting of data monitoring committees’ roles, interim analysis and early
termination in pediatric clinical trials. BMC Pediatr. 2009;9:77. https://doi.org/
10.1186/1471-2431-9-77.
236. Choodari-Oskooei B, Parmar MKB, Royston P, Bowden J. Impact of lack-of-
benefit stopping rules on treatment effect estimates of two-arm multi-stage
(TAMS) trials with time to event outcome. Trials. 2013;14:23. https://doi.org/
10.1186/1745-6215-14-23.
237. Bratton DJ. Design issues and extensions of multi-arm multi-stage clinical
trials. 2015. https://discovery.ucl.ac.uk/1459437/.
238. Wason JMS, Jaki T. Optimal design of multi-arm multi-stage trials. Stat Med.
2012;31:4269–79. https://doi.org/10.1002/sim.5513.
239. Wason J, Stallard N, Bowden J, et al. A multi-stage drop-the-losers design
for multi-arm clinical trials. Stat Methods Med Res. 2014. https://doi.org/10.
1002/sim.6086.
240. Lehmacher W, Wassmer G. Adaptive sample size calculations in group
sequential trials. Biometrics. 1999;55:1286–90. https://doi.org/10.1111/j.0006-
341X.1999.01286.x.
241. Vandemeulebroecke M. An investigation of two-stage tests. Stat Sin. 2006;
16:933–51.
242. Graf AC, Bauer P, Glimm E, Koenig F. Maximum type 1 error rate inflation in
multiarmed clinical trials with adaptive interim sample size modifications.
Biom J. 2014;56:614–30. https://doi.org/10.1002/bimj.201300153.
243. Posch M, Bauer P. Adaptive two stage designs and the conditional error
function. Biom J. 1999;41:689–96. https://doi.org/10.1002/(SICI)1521-
4036(199910)41:6<689::AID-BIMJ689>3.0.CO;2-P.
244. Proschan MA, Hunsberger SA. Designed extension of studies based on
conditional power. Biometrics. 1995;51:1315–24. https://doi.org/10.2307/
2533262.
245. Brard C, Le Teuff G, Le Deley M-C, et al. Bayesian survival analysis in clinical
trials: what methods are used in practice? Clin Trials. 2016. https://doi.org/
10.1177/1740774516673362.
246. Wagenmakers E-J, Gronau QF, Stefan A, et al. A Bayesian perspective on the
proposed FDA guidelines for adaptive clinical trials. 2018. https://www.
bayesianspectacles.org/a-bayesian-perspective-on-the-proposed-fda-
guidelines-for-adaptive-clinical-trials/.
247. FDA. Guidance, for the use of Bayesian statistics in medical device clinical
trials. 2010. https://www.fda.gov/downloads/MedicalDevices/
DeviceRegulationandGuidance/GuidanceDocuments/ucm071121.pdf.
248. Whitehead J. Overrunning and underrunning in sequential clinical trials.
Control Clin Trials. 1992;13:106–21. https://doi.org/10.1016/0197-
2456(92)90017-T.
249. Hampson LV, Jennison C. Group sequential tests for delayed responses
(with discussion). J R Stat Soc Ser B Stat Methodol. 2013;75:3–54. https://doi.
org/10.1111/j.1467-9868.2012.01030.x.
250. Emerson S, Fleming T. Parameter estimation following group sequential
hypothesis testing. Biometrika. 1990;77:875–92. https://doi.org/10.1093/
biomet/77.4.875.
251. Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M. Viscum
album [L.] extract therapy in patients with locally advanced or metastatic
pancreatic cancer: a randomised clinical trial on overall survival. Eur J
Cancer. 2013;49:3788–97. https://doi.org/10.1016/j.ejca.2013.06.043.
252. MacArthur RD, Hawkins TN, Brown SJ, et al. Efficacy and safety of crofelemer
for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a
randomized, double-blind, placebo-controlled, two-stage study. HIV Clin
Trials. 2013;14:261–73. https://doi.org/10.1310/hct1406-261.
253. Brannath W, Zuber E, Branson M, et al. Confirmatory adaptive designs with
Bayesian decision tools for a targeted therapy in oncology. Stat Med. 2009;
28:1445–63. https://doi.org/10.1002/sim.3559.
254. Marcus R, Eric P, Gabriel K. On closed testing procedures with special
reference to ordered analysis of variance. Biometrika. 1976;63:655–60.
https://doi.org/10.1093/biomet/63.3.655.
255. Simes RJ. An improved Bonferroni procedure for multiple tests of significance.
Biometrika. 1986;73:751. https://doi.org/10.1093/biomet/73.3.751.
256. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy
for lung cancer. Cancer Discov. 2011;1:44–53. https://doi.org/10.1158/2159-
8274.CD-10-0010.
257. Pushpakom S, Kolamunnage-Dona R, Taylor C, TAILoR Study Group, et al.
TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency
Virus [HIV]): an adaptive-design, dose-ranging phase IIb randomized trial of
telmisartan for the reduction of insulin resistance in HIV-positive individuals
on combination antiretroviral therapy. Clin Infect Dis. 2019;3:ciz589. https://
doi.org/10.1093/cid/ciz589.
Dimairo et al. Trials          (2020) 21:528 Page 33 of 34
258. James ND, Sydes MR, Clarke NW, STAMPEDE investigators, et al. Addition of
docetaxel, zoledronic acid, or both to first-line long-term hormone therapy
in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm,
multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.
https://doi.org/10.1016/S0140-6736(15)01037-5.
259. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for
evaluating multiple treatments. JAMA. 2015;313:1619–20. https://doi.org/10.
1001/jama.2015.2316.
260. Gilson C, Chowdhury S, Parmar MKB, Sydes MR, STAMPEDE Investigators.
Incorporating Biomarker Stratification into STAMPEDE: an adaptive multi-
arm, multi-stage trial platform. Clin Oncol (R Coll Radiol). 2017;29:778–86.
https://doi.org/10.1016/j.clon.2017.10.004.
261. Pemberton VL, Evans F, Gulin J, et al. Performance and predictors of
recruitment success in National Heart, Lung, and Blood Institute’s
cardiovascular clinical trials. Clin Trials. 2018;15:444–51. https://doi.org/10.
1177/1740774518792271.
262. de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir
for treatment of influenza in hospitalized patients. Clin Infect Dis. 2014;59:
e172–85. https://doi.org/10.1093/cid/ciu632.
263. Harvey LA. Statistical testing for baseline differences between randomised
groups is not meaningful. Spinal Cord. 2018;56:919. https://doi.org/10.1038/
s41393-018-0203-y.
264. Senn S. Testing for baseline balance in clinical trials. Stat Med. 1994;13:
1715–26. https://doi.org/10.1002/sim.4780131703.
265. de Boer MR, Waterlander WE, Kuijper LDJ, Steenhuis IH, Twisk JW. Testing
for baseline differences in randomized controlled trials: an unhealthy
research behavior that is hard to eradicate. Int J Behav Nutr Phys Act. 2015;
12:4. https://doi.org/10.1186/s12966-015-0162-z.
266. Altman DG. Comparability of randomised groups. Stat. 1985;34:125. https://
doi.org/10.2307/2987510.
267. Koch A. Confirmatory clinical trials with an adaptive design. Biom J. 2006;48:
574–85. https://doi.org/10.1002/bimj.200510239.
268. Chang M, Chow S-C, Pong A. Adaptive design in clinical research: issues,
opportunities, and recommendations. J Biopharm Stat. 2006;16:299–309,
discussion 311-2. https://doi.org/10.1080/10543400600609718.
269. Gallo P, Chuang-Stein C. What should be the role of homogeneity testing in
adaptive trials? Pharm Stat. 2009;8:1–4. https://doi.org/10.1002/pst.342.
270. Friede T, Henderson R. Exploring changes in treatment effects across design
stages in adaptive trials. Pharm Stat. 2009;8:62–72. https://doi.org/10.1002/
pst.332.
271. Wang S-J, Brannath W, Brückner M, et al. Unblinded adaptive statistical
information design based on clinical endpoint or biomarker. Stat Biopharm
Res. 2013;5:293–310. https://doi.org/10.1080/19466315.2013.791639.
272. Parker RA. Testing for qualitative interactions between stages in an adaptive
study. Stat Med. 2010;29:210–8. https://doi.org/10.1002/sim.3757.
273. Gonnermann A, Framke T, Großhennig A, Koch A. No solution yet for
combining two independent studies in the presence of heterogeneity. Stat
Med. 2015;34:2476–80. https://doi.org/10.1002/sim.6473.
274. Gamble C, Krishan A, Stocken D, et al. Guidelines for the content of
statistical analysis plans in clinical trials. JAMA. 2017;318:2337–43. https://doi.
org/10.1001/jama.2017.18556.
275. DeMets DL, Cook TD, Buhr KA. Guidelines for statistical analysis plans. JAMA.
2017;318:2301–3. https://doi.org/10.1001/jama.2017.18954.
276. ICH. ICH E9: statistical principles for clinical trials. 1998. https://www.ich.org/
fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_
Guideline.pdf.
277. Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design considerations for
adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698. https://doi.
org/10.1136/bmj.k698.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Dimairo et al. Trials          (2020) 21:528 Page 34 of 34
